

# BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [info.bmjopen@bmj.com](mailto:info.bmjopen@bmj.com)

# BMJ Open

## Association between physical activity and musculoskeletal pain: an analysis of international data from the ASAP survey

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-059525
Article Type:	Original research
Date Submitted by the Author:	22-Nov-2021
Complete List of Authors:	Rhim, Hye Chang; Metrowest Medical Center; Tufts University School of Medicine Tenforde, Adam; Harvard Medical School, Department of Physical Medicine and Rehabilitation; Spaulding Rehabilitation Hospital Mohr, Lisa; Goethe University Frankfurt, Department of Sports Medicine Hollander, Karsten; MSH Medical School Hamburg, Institute of Interdisciplinary Exercise Science and Sports Medicine Vogt, Lutz; Goethe-Universität Frankfurt am Main, Department of Sports Medicine Groneberg, David; Goethe University Frankfurt, Institut of Occupational Medicine, Social Medicine and Environmental Medicine Wilke, Jan; Goethe University Frankfurt, Department of Sports Medicine
Keywords:	SPORTS MEDICINE, REHABILITATION MEDICINE, Musculoskeletal disorders < ORTHOPAEDIC & TRAUMA SURGERY, PAIN MANAGEMENT

SCHOLARONE™  
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1  
2  
3 **Association between physical activity and musculoskeletal pain: an**  
4  
5  
6 **analysis of international data from the ASAP survey**  
7

8 Hye Chang Rhim\*, Adam Tenforde\*, Lisa Mohr, Karsten Hollander, Lutz Vogt, David A.  
9  
10 Groneberg, Jan Wilke†  
11

12  
13 \* The first two authors equally contributed to this work  
14  
15

16  
17  
18 Hye Chang Rhim, MetroWest Medical Center, Tufts University School of Medicine,  
19 Framingham, MA, USA  
20

21 Adam Tenforde, Department of Physical Medicine and Rehabilitation, Harvard Medical  
22 School/Spaulding Rehabilitation Hospital, Boston, MA, USA  
23

24 Lisa Mohr, Department of Sports Medicine, Goethe University Frankfurt, Frankfurt, Germany  
25

26 Karsten Hollander, Institute of Interdisciplinary Exercise Science and Sports Medicine, Medical  
27 School Hamburg, Hamburg, Germany  
28

29 Lutz Vogt, Department of Sports Medicine, Goethe University Frankfurt, Frankfurt, Germany  
30

31 David A. Groneberg, Division of Preventive and Sports Medicine, Institute of Occupational,  
32 Social, and Environmental Medicine, Goethe University, Frankfurt, Germany  
33

34 Jan Wilke, Department of Sports Medicine, Goethe University Frankfurt, Frankfurt, Germany  
35  
36  
37

38 ‡ Corresponding author: Jan Wilke, Department of Sports Medicine, Goethe University  
39 Frankfurt, Frankfurt, Germany, Email: [wilke@sport.uni-frankfurt.de](mailto:wilke@sport.uni-frankfurt.de)  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## ABSTRACT

**Objective:** To investigate the association of physical activity (PA) with musculoskeletal pain (MSK-pain).

**Design:** Cross-sectional study

**Setting:** 14 countries (Argentina, Australia, Austria, Brazil, Chile, France, Germany, Italy, the Netherlands, Singapore, South Africa, Spain, Switzerland, and the United States of America)

**Participants:** Individuals aged 18 or older living in participating countries. Recruitment was performed online using promotion by health-related organizations, mailing lists, and social media advertising.

**Primary and secondary outcome measures:** PA volumes were assessed with an adapted version of the Nordic physical activity questionnaire-short questionnaire. Prevalence of MSK-pain was captured by means of a 20-item checklist of body locations. Based on the WHO recommendation on PA, participants were classified as non-compliers (0-150 min/week), compliers (150-300 min/week), double compliers (300-450 min/week), triple compliers (450-600 min/week), quadruple compliers (600-750 min/week), quintuple compliers (750-900 min/week), and top compliers (more than 900 min/week). Multivariate logistic regression was used to obtain adjusted odds ratios of the association between PA and MSK-pain for each body location, correcting for age, sex, employment status, and depression risk.

**Results:** Compared to non-compliers, individuals with simple compliance had smaller odds of MSK-pain in one location (thoracic pain, OR 0.77). Double compliance was associated with reduced pain occurrence in six locations (elbow, OR 0.70; forearm, OR 0.63; wrist, OR 0.74; hand, OR 0.57; fingers, OR 0.72; abdomen, OR 0.61). Triple to top compliance was also linked with lower odds of MSK-pain (five locations in triple compliance, three in quadruple compliance, two in quintuple compliance, three in top compliance), but, at the same time, presented increased odds of MSK-pain in some of the other locations.

**Conclusion:** A dose of 300-450 min WHO-equivalent PA/week may be optimal to reduce MSK-pain. Excessive doses of PA may have harmful effects for certain body locations.

### Strengths and Limitations of this study

- This is the first large-scale analysis of associations between MSK pain and PA considering multiple anatomical locations
- Large sample size enabled to investigate the associations between different degrees of compliance to physical activity recommended by WHO and MSK-pain
- Administration of the survey in 14 countries allowed participation of diverse populations
- Self-reported data may be subject to recall bias
- Cross-sectional observational design prohibits causal inference

For peer review only

## INTRODUCTION

Musculoskeletal pain (MSK-pain) is a common condition that can have negative physical, psychological, and social impacts.<sup>1</sup> A summary of previous epidemiological studies conducted with diverse techniques and populations revealed that the prevalence of MSK-pain was approximately 30%.<sup>2</sup> One study reported 15% of 20–72-year-olds were pain-free whereas 15% had MSK-pain every day during the previous year and 58% reported MSK-pain within the past week.<sup>3</sup> Musculoskeletal impairments may contribute to functional limitations particularly in developed countries.<sup>2</sup> A separate investigation reported that musculoskeletal conditions accounted for 40% of all chronic conditions and contributed to over half of causes for long-term disability.<sup>4</sup> It has been reported that disability-adjusted life-years (DALYs), which reflects the years of life lost due to premature mortality and years of life lived with disability, increased by 62% between 1990 and 2016 around the world with 20% surge during the ten-year interval from 2006 to 2016.<sup>5</sup> Given the aging of global population, the burden of MSK disorders is expected to further increase in the future.<sup>6</sup>

Achieving sufficient physical activity (PA) is associated with a variety of positive health outcomes such as substantial risk reduction in all-cause mortality<sup>7</sup> as well as multiple chronic diseases including type 2 diabetes and metabolic syndrome,<sup>8</sup> cancer,<sup>8</sup> and cardiovascular disease.<sup>9</sup> In the light of these positive impacts, World Health Organization (WHO) recommends 150-300 min of moderate-intensity PA, or 75-150 min of vigorous-intensity PA, or aerobic PA with some combination of moderate and vigorous intensities.<sup>10</sup> PA is also considered one of the most important strategies to prevent and manage MSK pain.<sup>11</sup> However, most studies focused on the association of PA with non-communicable disease, and there is a literature gap regarding MSK-pain. Furthermore, it is still less clear whether these amounts are sufficient to elicit benefits

1  
2  
3 in terms of addressing MSK-pain. The few available studies examining the relation of regular PA  
4 and MSK-pain tended to focus on influence of PA for specific location or diagnoses such as low  
5 back pain, neck pain, or osteoarthritis and found inconsistent results.<sup>12</sup> Other studies have  
6  
7 evaluated the associations between PA and pain in occupational settings such as among physical  
8 therapists or teaching staff.<sup>13 14</sup> Particularly, the interplay between the volume of PA and MSK-  
9 pain within the general population has been less explored.

10  
11  
12 The purpose of this study was to investigate the association of total PA with MSK-pain  
13 by anatomical location (upper vs lower extremity). We hypothesize that greater time spent in PA  
14 would reduce overall MSK-pain, but excess time performing PA might contribute to higher pain  
15 resulting from associated overuse injuries  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27

## 28 **METHODS**

### 29 *Study Design*

30  
31  
32 This article presents an analysis of pre-pandemic baseline data on PA and MSK-pain  
33 assessed during the ASAP (Activity and Health during the SARS-CoV-2 Pandemic) survey. It  
34 was performed between April 3 and May 9, 2020, including participants from 14 countries  
35 (Argentina, Australia, Austria, Brazil, Chile, France, Germany, Italy, the Netherlands, Singapore,  
36 South Africa, Spain, Switzerland, and the United States of America (USA)).<sup>15-18</sup> Ethical approval  
37 was obtained from the ethics committees of the study center and collaborating institutions. All  
38 participants provided digital informed consent.  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50

### 51 *Participants*



1  
2  
3 Eligibility for participation in the ASAP survey was limited to individuals aged 18 or  
4 older living in participating countries. Recruitment was performed online using promotion by  
5 health-related organizations, mailing lists, and social media advertising (e.g. Facebook,  
6 Instagram, Twitter).  
7  
8  
9  
10  
11  
12  
13

### 14 *Questionnaire*

15  
16 To capture PA, the ASAP survey incorporated an adapted version of the Nordic Physical  
17 Activity Questionnaire-short (NPAQ-short). In detail, with its four questions, the instrument  
18 retrospectively assessed the amounts of moderate and combined moderate and vigorous activities  
19 (min/week) during leisure and occupational time. The NPAQ-short has been shown to be reliable  
20 (test-retest reliability:  $\rho = 0.80$  to  $0.82$ ) and valid for observing compliance with the WHO  
21 recommendations on PA.<sup>19</sup>  
22  
23  
24  
25  
26  
27  
28  
29

30  
31 Prevalence of MSK-pain was captured by means of binary responses (yes/no) to an  
32 adapted 20-item checklist from a consensus statement on epidemiological injury reporting.<sup>20</sup>  
33 Body locations were categorized as follows: neck/cervical spine, shoulder, upper arm, elbow,  
34 forearm, wrist, hand, fingers, thoracic spine, ribs, lower back, abdomen, pelvis/gluteal, hip,  
35 groin, thigh, knee, lower leg, ankle/Achilles tendon, foot/toe.  
36  
37  
38  
39  
40  
41  
42  
43

### 44 *Data Processing and Statistical Analysis*

45  
46 Self-reported PA was categorized as multiples of compliance with WHO guidelines  
47 which recommend 150-300 minutes/week of moderate activity, 75-150 minutes/week of  
48 vigorous activity, or any adequate combination of both.<sup>10</sup> We used the formula (moderate-to-  
49 vigorous PA – vigorous PA) + vigorous PA \*2 to classify participants as non-compliers (0-150  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 min/week), compliers (150-300 min/week), double compliers (300-450 min/week), triple  
4  
5 compliers (450-600 min/week), quadruple compliers (600-750 min/week), quintuple compliers  
6  
7 (750-900 min/week), and top compliers (more than 900 min/week).  
8  
9

10 For each body region, univariate logistic regression was conducted to calculate the  
11 unadjusted odds ratio (OR) of the association between pain (dependent variable) and PA. In a  
12 similar way, univariate logistic regression was then used to identify associations of pain  
13 (dependent variable) and potential confounding variables (sex, age, employment status,  
14 depression risk). Finally, multivariate logistic regression was performed including these  
15 confounding variables (if relevant) to obtain the adjusted ORs and 95% confidence interval (CI)  
16 of the association between the volume of PA and pain. All data analyses were conducted using  
17 SPSS 22 (SPSS INC., Armonk, NY, USA), and the significance level was set to  $\alpha = 0.05$ .  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30

### 31 *Patient and Public Involvement*

32  
33 Members of the target population without medical background were involved in the  
34 designing phase of the ASAP questionnaire. They completed the preliminary version of the  
35 survey and helped refine and clarify wording of the survey, an involvement which was intended  
36 to increase face validity.  
37  
38  
39  
40  
41  
42  
43

## 44 **RESULTS**

45  
46 Valid datasets were identified for 13,741 participants ( $38 \pm 15$  years, 59% females). 2604  
47 individuals did not meet the WHO recommendation of PA while  $n=2735$  belonged to 150-300  
48 min group,  $n=1957$  to 300-450 min group,  $n=1749$  to 450-600 min group,  $n=1066$  to 600-750  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 min group, n=849 to 750-900 min group, and n=2781 to 900+ min group. Comprehensive  
4 results are summarized in the Table 1 and 2.  
5  
6

7  
8 Compared to inactive individuals, simple compliance was associated with reduced MSK-  
9 pain in one body location (thoracic pain, OR 0.77, Table 1). Double compliance increased the  
10 number of locations with less pain to six (elbow, OR 0.70; forearm, OR 0.63; wrist, OR 0.74;  
11 hand, OR 0.57; fingers, OR 0.72; abdomen, OR 0.61). Although higher amounts of PA were  
12 linked to lower pain levels to a variable degree (five body locations in triple compliance, three in  
13 quadruple compliance, two in quintuple compliance, three in top compliance), they also showed  
14 increased pain in other locations. Specifically, triple compliance was associated with higher pain  
15 in thigh (OR 1.41), knee (OR 1.25), and ankle/Achilles tendon (OR 1.47). Quadruple compliance  
16 increased pain locations to four, quintuple compliance to six, and top compliance to seven.  
17  
18

19 Triple compliance was associated with lower odds to have a total of 5 or more (OR 0.75)  
20 or 10 or more (OR 0.36) pain locations, and quadruple compliance was associated with lower  
21 odds to have 5 or more pain locations (OR 0.73). However, quintuple and top compliances were  
22 associated with higher odds of having a minimum one pain location (OR 1.28 and 1.30,  
23 respectively).  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41

## 42 **DISCUSSION**

43  
44 The purpose of the present study was to understand the relation between PA and MSK-  
45 pain. Previous research focused on the impact of PA on specific locations of MSK-pain (e.g.,  
46 low back and neck<sup>21</sup>) or certain occupational settings.<sup>13 14</sup> Our large-scale multinational study is  
47 novel in that it identified the associations between different degrees of compliance to PA  
48 recommended by WHO and multiple body locations in the general population.  
49  
50  
51  
52  
53  
54  
55  
56  
57

1  
2  
3 Simple guideline compliance (150-300 min per week) was weakly associated with MSK pain,  
4 showing lower odds of developing pain only in thoracic spine but higher odds in foot/toes. In  
5  
6 contrast, double compliance (300-450 min per week) substantially increased the number of  
7  
8 beneficial associations to six and thus seems to represent the optimal dose when PA is  
9  
10 undertaken to prevent MSK. Finally, higher levels of PA (triple to top compliance) were  
11  
12 associated with less odds of developing pain in multiple upper body locations but paradoxically  
13  
14 contributed to higher odds of lower extremity pain. Notably, participating in 300-600 min of PA  
15  
16 per week was associated with lower odds of developing pain in upper extremities, neck, and  
17  
18 thoracic and lumbar spine. In contrast, participating in greater than 450 min of PA per week was  
19  
20 associated with higher odds of developing pain in the lower extremity.  
21  
22  
23  
24  
25  
26  
27

#### 28 *Time spent in PA and pain in neck, back, and upper extremity*

29  
30  
31 A previous systematic review showed that there was limited evidence for no association  
32  
33 between PA and neck pain.<sup>21</sup> However, our study found that participating in PA between 450-  
34  
35 900+ min was associated with lower odds of developing pain in neck/cervical spine. Several  
36  
37 epidemiological studies have demonstrated that certain postures sustained for prolonged duration  
38  
39 combined with sedentary lifestyle were associated with neck pain.<sup>22-24</sup> Therefore, increased PA  
40  
41 levels may be helpful to consider in those at risk for neck pain.  
42  
43  
44

45 Association between PA and thoracic spine has been less explored,<sup>25</sup> but a recent  
46  
47 observational study found that PA less than 150 min per week was associated with reduced  
48  
49 thoracic mobility.<sup>26</sup> Our findings build on previous research in that PA less than 150 min per  
50  
51 week is also associated with higher odds of developing pain in the thoracic spine.  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 While it is generally accepted that PA and exercise are beneficial in the management of  
4 acute and chronic low back pain, a previous systematic review could not identify either positive  
5 or negative relationship.<sup>27</sup> One study suggested that the relationship between the level of activity  
6 and back pain might be explained by a U-shaped curve that suggests both low and excessive PA  
7 may increase the risk of low back pain.<sup>28</sup> Our findings partly support this concept as PA of 450-  
8 750 min was associated with lower odds of low back pain while lower or higher PA than that  
9 range did not have significant association.  
10  
11  
12  
13  
14  
15  
16  
17  
18

19 Beneficial effects of PA in the range of 300-600 min were also noted in several locations  
20 in the upper extremity such as elbow, forearm, wrist, hand, and fingers. PA exceeding 750 min  
21 was associated with higher odds of shoulder pain. The underlying mechanisms of how PA  
22 modulates pain are not completely understood, but several pathways have been proposed.  
23  
24 Animal study findings suggest regular PA may act on the central nervous system (CNS) and alter  
25 rate of pain hypersensitivity, dysregulation of pain modulation, and development of chronic  
26 pain.<sup>29-31</sup> In humans, it has been proposed that PA may intervene excitability and inhibition in the  
27 CNS,<sup>32-34</sup> and anti-inflammatory and antioxidant effects of regular PA might diminish the  
28 processes contributing to central sensitization.<sup>35-37</sup> Other proposed mechanisms in humans  
29 include the activation of opioid and serotonin pathways<sup>38</sup> or involvement of endocannabinoid  
30 system<sup>39</sup> induced from regular PA which could exert analgesic effects. While further research is  
31 needed to elucidate how much and what type of PA can induce such changes to modulate pain,  
32 our results suggest that PA between 300-600 mins per week may be sufficient for spinal  
33 conditions and upper extremity pain, with PA exceeding 750 min associated with higher  
34 likelihood of shoulder pain.  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

### *Association of PA and lower extremity pain*

The association of PA to lower extremity pain was different than what was observed for upper extremity and spine conditions. Our results suggest PA exceeding 450 min was associated with higher odds of MSK-pain in lower extremity. These findings may be partially explained by higher amounts of PA are likely to involve greater use of the lower extremity. In the United States, it has been reported that walking is the most popular form of exercise followed by biking, yard work, strength training, dancing, and running, which are activities that commonly place physical demands through the lower extremity.<sup>40</sup> Running is one of the most popular exercises in the world and has been shown to result in lower extremity pain in multiple anatomical locations with nearly all (94.7% of runners) reporting experience of pain at least once after running.<sup>41</sup>

We also observed that greater PA was associated with a higher number of sites of MSK-pain in the lower extremity. A dose response was observed: 450-600 min was associated with pain in three anatomical regions, 600-750 min with pain in four anatomical regions, 750-900 min with five anatomical regions, and 900+ min with six anatomical regions. The optimal PA level to reduce pain in those with existing musculoskeletal lower extremity pain is unknown. A prior study reported that a minimum of 45 total moderate-vigorous min per week was sufficient to elicit improved or sustained high function with lower-extremity symptoms regardless of age, gender, body mass index, or presence of knee osteoarthritis.<sup>42</sup> Our findings of PA ranging from 150-450 min not increasing the odds of having pain in the lower extremities suggest this range might be appropriate to be safe and promote other health benefits.

### *Clinical implication*

1  
2  
3 While the WHO 2020 guidelines on PA recommend 150-300 min of moderate-intensity  
4 PA, or 75-150 min of vigorous-intensity PA, or some equivalent combination of moderate-  
5 intensity and vigorous-intensity aerobic PA per week for optimal health outcomes,<sup>10</sup> the current  
6 study suggests that more PA beyond the WHO recommendation may be necessary to decrease  
7 the odds of developing pain particularly in the upper extremity. Our findings suggest a target of  
8 300-450 min of PA per week could be optimal for preventing pain in the upper extremity without  
9 clear associated higher rate of lower extremity pain. Recognizing concerns on higher prevalence  
10 of pain in low back, neck, and thoracic spine increased during the COVID-19 pandemic,<sup>17</sup> PA  
11 target of the higher target of 450 min of weekly exercise may be helpful in this population. Our  
12 results suggest exceeding 450 min of PA may not be advisable for those with increased concern  
13 for lower extremity pain.  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30

### 31 *Limitation*

32  
33 While our findings are derived from a large-scale multinational study of participants, we  
34 do note potential limitations. Self-report of PA and MSK-pain are limited by reporting bias and  
35 inaccuracy including risk for over-reporting level of PA.<sup>43 44</sup> The cross-sectional study design  
36 limits our understanding between PA and the etiology of MSK-pain. We are limited in ability in  
37 discriminating the types of PA to report of MSK-pain by anatomical locations. Further  
38 prospective cohort or interventional studies may further elucidate the best form and dose of PA  
39 to address MSK-pain by anatomical location and specific musculoskeletal injury, and  
40 additionally investigate the role of MSK-pain intensity instead of using a binary (yes/no)  
41 classification.  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## CONCLUSION

Our findings suggest that PA time above the WHO recommendations may prevent pain in multiple locations such as neck, thoracic spine, low back, and in the upper extremities.

Especially, undertaking PA for 300-450 min per week may be most beneficial. However, selective individuals who are prone to injuries or suffer from existing degenerative changes in lower extremities may need to be more cautious when exercising above 450 min per week.

For peer review only



1  
2  
3  
4  
5  
6 **Acknowledgment:** The authors acknowledge the valuable help from the following authors with  
7 promoting ASAP survey for data collection (in alphabetical order): Benedict Tan, Bernhard  
8 Novak, Celso Ramírez, Chiara Fossati, Christoph Heidt, Daniel E. Lieberman, David Jimenez-  
9 Pavon, Evert Verhagen, Fabio Pigozzi, Falk Richter, Fernando Laíño, Johannes Jaunig, Julian  
10 David Pillay, Luiz Carlos Hespanhol Junior, Marcela González-Gross, Matteo Sattler, Mireille  
11 van Poppel, Pascal Edouard, Steffen Willwacher

12  
13  
14 **Funding:** This research received no external funding.

15  
16 **Data Availability Statement:** Data are available upon reasonable request

### 17 **Ethics Statements**

18  
19 -Ethics approval: This study was approved by the ethics committee of the lead university  
20 (Goethe University Frankfurt) and also locally from the partners in the participating countries.

21  
22 -Digital informed consent was obtained from all subjects involved in the study.

23  
24 **Authors Contribution:** HCR/AT: data collection, interpretation, drafting and critical revision of  
25 the manuscript, LM, KH, LV, DG: data collection, critical revision of the manuscript, JW:  
26 conception/design, data collection, interpretation, critical revision of the manuscript  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## REFERENCES

1. Paananen M, Taimela S, Auvinen J, et al. Impact of self-reported musculoskeletal pain on health-related quality of life among young adults. *Pain Med* 2011;12(1):9-17.
2. Cimmino MA, Ferrone C, Cutolo M. Epidemiology of chronic musculoskeletal pain. *Best Pract Res Clin Rheumatol* 2011;25(2):173-83.
3. Natvig B, Nessiøy I, Bruusgaard D, et al. Musculoskeletal complaints in a population. Occurrence and localization. *Tidsskr Nor Laegeforen* 1994;114(3):323-27.
4. Badley EM, Wang PP. Arthritis and the aging population: projections of arthritis prevalence in Canada 1991 to 2031. *J Rheumatol* 1998;25(1):138-44.
5. Collaborators GDaH. Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet* 2017;390(10100):1260-344. doi: 10.1016/s0140-6736(17)32130-x [published Online First: 2017/09/19]
6. Smith E, Hoy DG, Cross M, et al. The global burden of other musculoskeletal disorders: estimates from the Global Burden of Disease 2010 study. *Ann Rheum Dis* 2014;73(8):1462-9. doi: 10.1136/annrheumdis-2013-204680 [published Online First: 2014/03/05]
7. Ekelund U, Tarp J, Steene-Johannessen J, et al. Dose-response associations between accelerometer measured physical activity and sedentary time and all cause mortality: systematic review and harmonised meta-analysis. *BMJ* 2019;366
8. Lee I-M, Shiroma EJ, Lobelo F, et al. Effect of physical inactivity on major non-communicable diseases worldwide: an analysis of burden of disease and life expectancy. *Lancet* 2012;380(9838):219-29.
9. Kyu HH, Bachman VF, Alexander LT, et al. Physical activity and risk of breast cancer, colon cancer, diabetes, ischemic heart disease, and ischemic stroke events: systematic review and dose-response meta-analysis for the Global Burden of Disease Study 2013. *BMJ* 2016;354
10. Bull FC, Al-Ansari SS, Biddle S, et al. World Health Organization 2020 guidelines on physical activity and sedentary behaviour. *Br J Sports Med* 2020;54(24):1451-62.
11. Lin I, Wiles L, Waller R, et al. Patient-centred care: the cornerstone for high-value musculoskeletal pain management. *Br J Sports Med* 2020;54(21):1240-42. doi: 10.1136/bjsports-2019-101918 [published Online First: 2020/06/27]
12. Geneen LJ, Moore RA, Clarke C, et al. Physical activity and exercise for chronic pain in adults: an overview of Cochrane Reviews. *Cochrane Database Syst Rev* 2017(4)
13. Ezzatvar Y, Calatayud J, Andersen L, et al. Are moderate and vigorous leisure-time physical activity associated with musculoskeletal pain? a cross-sectional study among 981 physical therapists. *Am J Health Promot* 2020;34(1):67-70.
14. Tami AM, Bika Lele EC, Mekoulou Ndongo J, et al. Epidemiology of Musculoskeletal Disorders among the Teaching Staff of the University of Douala, Cameroon: Association with Physical Activity Practice. *Int J Environ Res Public Health* 2021;18(11):6004.
15. Wilke J, Mohr L, Tenforde AS, et al. Activity and health during the SARS-CoV2 pandemic (ASAP): study protocol for a multi-national network trial. *Front Med* 2020;7:302.

16. Wilke J, Mohr L, Tenforde AS, et al. Restrict exercise! Preferences regarding digital home training programs during confinements associated with the COVID-19 pandemic. *Int J Environ Res Public Health* 2020;17(18):6515.
17. Wilke J, Mohr L, Tenforde AS, et al. A pandemic within the pandemic? Physical activity levels substantially decreased in countries affected by COVID-19. *Int J Environ Res Public Health* 2021;18(5):2235.
18. Wilke J, Hollander K, Mohr L, et al. Drastic reductions in mental well-being observed globally during the COVID-19 pandemic: results from the ASAP survey. *Front Med* 2021;8:246.
19. Danquah IH, Petersen CB, Skov SS, et al. Validation of the NPAQ-short—a brief questionnaire to monitor physical activity and compliance with the WHO recommendations. *BMC Public Health* 2018;18(1):1-10.
20. Bahr R, Clarsen B, Derman W, et al. International Olympic Committee consensus statement: methods for recording and reporting of epidemiological data on injury and illness in sports 2020 (including the STROBE extension for sports injury and illness surveillance (STROBE-SIIS)). *Orthop J Sports Med* 2020;8(2):2325967120902908.
21. Sitthipornvorakul E, Janwantanakul P, Purepong N, et al. The association between physical activity and neck and low back pain: a systematic review. *Eur Spine J* 2011;20(5):677-89.
22. Ortiz-Hernández L, Tamez-González S, Martínez-Alcántara S, et al. Computer use increases the risk of musculoskeletal disorders among newspaper office workers. *Arch Med Res* 2003;34(4):331-42.
23. Janwantanakul P, Pensri P, Jiamjarasrangsri W, et al. Associations between prevalence of self-reported musculoskeletal symptoms of the spine and biopsychosocial factors among office workers. *J Occup Health* 2009;0901270054-54.
24. Cagnie B, Danneels L, Van Tiggelen D, et al. Individual and work related risk factors for neck pain among office workers: a cross sectional study. *Eur Spine J* 2007;16(5):679-86.
25. Briggs AM, Smith AJ, Straker LM, et al. Thoracic spine pain in the general population: prevalence, incidence and associated factors in children, adolescents and adults. A systematic review. *BMC Musculoskelet Disord* 2009;10(1):1-12.
26. Heneghan NR, Baker G, Thomas K, et al. What is the effect of prolonged sitting and physical activity on thoracic spine mobility? An observational study of young adults in a UK university setting. *BMJ Open* 2018;8(5):e019371.
27. Hendrick P, Milosavljevic S, Hale L, et al. The relationship between physical activity and low back pain outcomes: a systematic review of observational studies. *Eur Spine J* 2011;20(3):464-74.
28. Heneweer H, Vanhees L, Picavet HSJ. Physical activity and low back pain: a U-shaped relation? *Pain* 2009;143(1-2):21-25.
29. Bobinski F, Ferreira TAA, Córdova MM, et al. Role of brainstem serotonin in analgesia produced by low-intensity exercise on neuropathic pain following sciatic nerve injury in mice. *Pain* 2015;156(12):2595.
30. Sluka KA, O'Donnell JM, Danielson J, et al. Regular physical activity prevents development of chronic pain and activation of central neurons. *J Appl Physiol* 2013;114(6):725-33.
31. Stagg NJ, Mata HP, Ibrahim MM, et al. Regular exercise reverses sensory hypersensitivity in a rat neuropathic pain model: role of endogenous opioids. *Anesthesiology* 2011;114(4):940-48.

- 1
- 2
- 3
- 4 32. Geva N, Defrin R. Enhanced pain modulation among triathletes: a possible explanation for
- 5 their exceptional capabilities. *Pain* 2013;154(11):2317-23.
- 6 33. Naugle KM, Ohlman T, Naugle KE, et al. Physical activity behavior predicts endogenous
- 7 pain modulation in older adults. *Pain* 2017;158(3):383-90.
- 8 34. Naugle KM, Riley JL. Self-reported physical activity predicts pain inhibitory and facilitatory
- 9 function. *Med Sci Sports Exerc* 2014;46(3):622.
- 10 35. Radak Z, Chung HY, Koltai E, et al. Exercise, oxidative stress and hormesis. *Ageing Res Rev*
- 11 2008;7(1):34-42.
- 12 36. Woods JA, Wilund KR, Martin SA, et al. Exercise, inflammation and aging. *Aging Dis*
- 13 2012;3(1):130.
- 14 37. Dhondt E, Danneels L, Van Oosterwijck S, et al. The influence of physical activity on the
- 15 nociceptive flexion reflex in healthy people. *Eur J Pain* 2021;25(4):774-89.
- 16 38. Tour J, Löfgren M, Mannerkorpi K, et al. Gene-to-gene interactions regulate endogenous
- 17 pain modulation in fibromyalgia patients and healthy controls-antagonistic effects
- 18 between opioid and serotonin-related genes. *Pain* 2017;158(7):1194-203. doi:
- 19 10.1097/j.pain.0000000000000896 [published Online First: 2017/03/11]
- 20 39. Tantimonaco M, Ceci R, Sabatini S, et al. Physical activity and the endocannabinoid system:
- 21 an overview. *Cell Mol Life Sci* 2014;71(14):2681-98.
- 22 40. Ham SA, Kruger J, Tudor-Locke C. Participation by US adults in sports, exercise, and
- 23 recreational physical activities. *J Phys Act Health* 2009;6(1):6-14.
- 24 41. Rhim HC, Kim SJ, Jeon JS, et al. Prevalence and risk factors of running-related injuries in
- 25 Korean non-elite runners: a cross-sectional survey study. *J Sports Med Phys Fitness*
- 26 2021;61(3):413-19. doi: 10.23736/s0022-4707.20.11223-4 [published Online First:
- 27 2020/08/04]
- 28 42. Dunlop DD, Song J, Lee J, et al. Physical activity minimum threshold predicting improved
- 29 function in adults with Lower-Extremity symptoms. *Arthritis Care Res* 2017;69(4):475-
- 30 83.
- 31 43. Valanou E, Bamia C, Trichopoulou A. Methodology of physical-activity and energy-
- 32 expenditure assessment: a review. *J Public Health* 2006;14(2):58-65.
- 33 44. Schmier J, Halpern M. Patient recall and recall bias of health state and health status. *Expert*
- 34 *Rev Pharmacoecon Outcomes Res.* 2004; 4 (2): 159–63.
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

**Table 1. Association of PA with MSK-Pain by Anatomical Locations**

Location of MSK-Pain	Dose of WHO Guideline-Based PA											
	150-300 min		300-450 min		450-600 min		600-750 min		750-900 min		900+ min	
	Crude OR (95% CI)	Adjusted OR (95% CI)	Crude OR (95% CI)	Adjusted OR (95% CI)	Crude OR (95% CI)	Adjusted OR (95% CI)	Crude OR (95% CI)	Adjusted OR (95% CI)	Crude OR (95% CI)	Adjusted OR (95% CI)	Crude OR (95% CI)	Adjusted OR (95% CI)
Neck/Cervical	0.89 (0.79-1.01)	0.99 (0.87-1.12)	0.76 (0.67-0.88)	0.89 (0.77-1.03)	0.66 (0.57-0.76)	<b>0.78</b> <b>(0.67-0.91)</b>	0.62 (0.52-0.74)	<b>0.75</b> <b>(0.62-0.90)</b>	0.63 (0.52-0.77)	0.82 (0.67-1.00)	0.59 (0.52-0.67)	<b>0.78</b> <b>(0.68-0.89)</b>
Shoulder	0.87 (0.75-1.00)	0.92 (0.79-1.06)	0.87 (0.74-1.02)	0.94 (0.79-1.10)	0.83 (0.71-0.99)	0.93 (0.79-1.11)	0.80 (0.66-0.98)	0.88 (0.72-1.08)	1.10 (0.90-1.34)	<b>1.27</b> <b>(1.04-1.56)</b>	0.98 (0.85-1.13)	<b>1.16</b> <b>(1.00-1.34)</b>
Upper arm	0.77 (0.60-1.00)	0.98 (0.76-1.27)	0.60 (0.44-0.81)	0.81 (0.60-1.11)	0.56 (0.41-0.77)	0.76 (0.54-1.05)	0.62 (0.42-0.89)	0.81 (0.55-1.19)	0.89 (0.63-1.28)	1.23 (0.85-1.80)	0.73 (0.56-0.94)	1.01 (0.77-1.33)
Elbow	0.73 (0.54-0.97)	0.77 (0.57-1.03)	0.64 (0.46-0.89)	<b>0.70</b> <b>(0.50-0.98)</b>	0.95 (0.70-1.30)	0.99 (0.72-1.37)	0.92 (0.64-1.32)	0.93 (0.64-1.37)	0.90 (0.60-1.34)	0.94 (0.62-1.42)	1.19 (0.93-1.53)	1.30 (0.99-1.70)
Forearm	0.91 (0.65-1.28)	1.08 (0.76-1.52)	0.53 (0.34-0.82)	<b>0.63</b> <b>(0.40-0.99)</b>	0.72 (0.47-1.07)	0.85 (0.55-1.30)	0.80 (0.50-1.29)	0.96 (0.59-1.55)	0.74 (0.43-1.26)	0.90 (0.52-1.54)	0.98 (0.70-1.36)	1.17 (0.82-1.65)
Wrist	0.86 (0.70-1.07)	1.07 (0.86-1.34)	0.57 (0.43-0.74)	<b>0.74</b> <b>(0.57-0.98)</b>	0.63 (0.48-0.82)	0.81 (0.62-1.07)	0.79 (0.58-1.06)	1.00 (0.74-1.37)	0.71 (0.50-0.99)	0.95 (0.67-1.34)	0.86 (0.70-1.07)	1.15 (0.91-1.44)
Hand	0.68 (0.53-0.88)	0.81 (0.62-1.05)	0.44 (0.32-0.61)	<b>0.57</b> <b>(0.40-0.79)</b>	0.47 (0.34-0.66)	<b>0.59</b> <b>(0.41-0.83)</b>	0.60 (0.41-0.87)	0.74 (0.50-1.09)	0.60 (0.40-0.91)	0.77 (0.50-1.18)	0.57 (0.44-0.75)	<b>0.74</b> <b>(0.56-0.99)</b>
Fingers	0.85 (0.66-1.10)	0.91 (0.70-1.19)	0.63 (0.46-0.86)	<b>0.72</b> <b>(0.52-0.99)</b>	0.65 (0.47-0.86)	<b>0.71</b> <b>(0.51-0.99)</b>	0.80 (0.56-1.14)	0.93 (0.65-1.34)	0.71 (0.48-1.07)	0.81 (0.53-1.22)	0.75 (0.58-0.98)	0.84 (0.64-1.11)
Thoracic spine	0.75 (0.63-0.90)	<b>0.77</b> <b>(0.64-0.93)</b>	0.83 (0.69-1.02)	0.90 (0.74-1.10)	0.71 (0.58-0.88)	<b>0.78</b> <b>(0.63-0.97)</b>	0.69 (0.54-0.89)	<b>0.74</b> <b>(0.57-0.97)</b>	0.54 (0.40-0.73)	<b>0.64</b> <b>(0.47-0.87)</b>	0.63 (0.52-0.76)	<b>0.77</b> <b>(0.63-0.93)</b>
Ribs	0.85 (0.59-1.21)	0.98 (0.68-1.42)	0.74 (0.49-1.11)	0.88 (0.58-1.34)	0.60 (0.38-0.95)	<b>0.74</b> <b>(0.46-1.17)</b>	1.04 (0.66-1.62)	1.18 (0.73-1.88)	0.69 (0.39-1.22)	0.88 (0.50-1.57)	0.78 (0.54-1.11)	0.90 (0.62-1.36)
Lower back	0.91 (0.80-1.03)	0.93 (0.82-1.06)	0.85 (0.73-0.97)	0.91 (0.78-1.05)	0.77 (0.67-0.90)	<b>0.84</b> <b>(0.72-0.97)</b>	0.69 (0.57-0.82)	<b>0.76</b> <b>(0.63-0.91)</b>	0.85 (0.71-1.03)	0.96 (0.79-1.16)	0.79 (0.70-0.90)	0.93 (0.81-1.06)
Abdomen	0.70 (0.52-0.95)	0.94 (0.69-1.28)	0.45 (0.31-0.67)	<b>0.61</b> <b>(0.41-0.91)</b>	0.68 (0.48-0.97)	0.97 (0.68-1.40)	0.67 (0.44-1.02)	0.89 (0.57-1.37)	0.91 (0.60-1.38)	1.33 (0.87-2.05)	0.60 (0.44-0.83)	0.82 (0.59-1.14)
Pelvis/Gluteals	1.00 (0.78-1.28)	1.11 (0.86-1.43)	0.77 (0.57-1.03)	0.86 (0.64-1.17)	0.92 (0.69-1.23)	1.13 (0.84-1.52)	1.02 (0.74-1.41)	1.15 (0.81-1.62)	0.96 (0.67-1.39)	1.19 (0.82-1.73)	1.10 (0.86-1.40)	<b>1.37</b> <b>(1.06-1.76)</b>
Hip	1.06 (0.87-1.30)	1.05 (0.85-1.29)	0.93 (0.74-1.17)	0.96 (0.76-1.21)	1.05 (0.84-1.32)	1.09 (0.87-1.38)	0.93 (0.71-1.22)	0.97 (0.73-1.29)	1.24 (0.94-1.63)	<b>1.37</b> <b>(1.03-1.81)</b>	0.97 (0.79-1.18)	1.17 (0.95-1.45)
Groin	0.94 (0.65-1.34)	1.04 (0.72-1.49)	0.72 (0.47-1.10)	0.80 (0.52-1.23)	0.98 (0.65-1.46)	1.05 (0.69-1.59)	1.08 (0.69-1.71)	1.20 (0.75-1.91)	1.31 (0.83-2.10)	1.40 (0.87-2.27)	1.28 (0.92-1.79)	1.40 (0.99-1.99)
Thigh	0.99 (0.75-1.31)	1.13 (0.85-1.51)	0.87 (0.63-1.19)	0.99 (0.71-1.38)	1.24 (0.92-1.68)	<b>1.41</b> <b>(1.03-1.92)</b>	1.39 (0.99-1.95)	<b>1.59</b> <b>(1.13-2.25)</b>	1.60 (1.13-2.27)	<b>1.82</b> <b>(1.28-2.61)</b>	1.37 (1.05-1.78)	<b>1.51</b> <b>(1.15-1.99)</b>
Knee	1.02 (0.88-1.19)	1.08 (0.92-1.25)	1.04 (0.88-1.22)	1.10 (0.93-1.30)	1.17 (0.99-1.37)	<b>1.25</b> <b>(1.06-1.50)</b>	1.12 (0.93-1.36)	<b>1.22</b> <b>(1.01-1.49)</b>	1.43 (1.18-1.75)	<b>1.55</b> <b>(1.27-1.90)</b>	1.16 (1.00-1.34)	<b>1.30</b> <b>(1.12-1.51)</b>
Lower leg	0.77 (0.59-1.00)	0.93 (0.71-1.21)	0.82 (0.62-1.07)	1.04 (0.78-1.39)	1.02 (0.77-1.34)	1.31 (0.98-1.73)	1.14 (0.83-1.55)	<b>1.43</b> <b>(1.04-1.97)</b>	0.95 (0.66-1.36)	1.22 (0.85-1.77)	1.03 (0.81-1.31)	<b>1.34</b> <b>(1.04-1.73)</b>
Ankle/Achilles	1.09 (0.87-1.36)	1.14 (0.90-1.43)	1.19 (0.93-1.52)	1.24 (0.96-1.59)	1.42 (1.12-1.81)	<b>1.47</b> <b>(1.14-1.88)</b>	1.48 (1.12-1.94)	<b>1.55</b> <b>(1.17-2.06)</b>	1.70 (1.28-2.26)	<b>1.79</b> <b>(1.34-2.40)</b>	1.69 (1.37-2.08)	<b>1.85</b> <b>(1.49-2.31)</b>
Foot/Toes	1.22 (0.99-1.52)	<b>1.28</b> <b>(1.02-1.60)</b>	1.12 (0.88-1.42)	1.25 (0.98-1.61)	1.08 (0.84-1.38)	1.24 (0.96-1.60)	1.10 (0.82-1.47)	1.26 (0.93-1.71)	1.23 (0.91-1.67)	<b>1.50</b> <b>(1.10-2.05)</b>	1.17 (0.94-1.45)	<b>1.53</b> <b>(1.22-1.92)</b>

Abbreviations: CI, Confidence Interval; MSK, Musculoskeletal; OR, Odds Ratio; PA, Physical Activity; WHO, World Health Organization

Footnote: A group of participants who did not meet the WHO recommendations of PA (i.e. PA less than 150 min per week) was set as the reference group. The model was adjusted for sex, age, employment status, and depression risk.

For peer review only

**Table 2. Association of PA with the Number of MSK-Pain Locations**

Number of MSK-Pain Locations	Dose of WHO Guideline-Based PA											
	150-300 min		300-450 min		450-600 min		600-750 min		750-900 min		900+ min	
	Crude OR (95% CI)	Adjusted OR (95% CI)	Crude OR (95% CI)	Adjusted OR (95% CI)	Crude OR (95% CI)	Adjusted OR (95% CI)	Crude OR (95% CI)	Adjusted OR (95% CI)	Crude OR (95% CI)	Adjusted OR (95% CI)	Crude OR (95% CI)	Adjusted OR (95% CI)
Minimum 1 location	1.06 (0.95-1.18)	1.10 (0.98-1.23)	1.04 (0.93-1.17)	1.12 (0.99-1.27)	1.01 (0.89-1.14)	1.11 (0.98-1.26)	0.92 (0.80-1.06)	1.04 (0.90-1.20)	1.09 (0.80-1.28)	<b>1.28</b> <b>(1.10-1.51)</b>	1.05 (0.94-1.17)	<b>1.30</b> <b>(1.16-1.45)</b>
Minimum 3 locations	0.89 (0.78-1.01)	0.97 (0.85-1.11)	0.80 (0.70-0.93)	0.90 (0.78-1.04)	0.80 (0.69-0.93)	0.93 (0.80-1.08)	0.86 (0.72-1.02)	1.00 (0.84-1.19)	0.93 (0.77-1.12)	1.12 (0.93-1.36)	0.88 (0.77-0.99)	1.08 (0.94-1.23)
Minimum 5 locations	0.76 (0.62-0.93)	0.84 (0.69-1.03)	0.65 (0.51-0.82)	<b>0.75</b> <b>(0.60-0.95)</b>	0.61 (0.48-0.78)	<b>0.73</b> <b>(0.57-0.93)</b>	0.74 (0.56-0.97)	0.85 (0.64-1.13)	0.87 (0.66-1.16)	1.09 (0.82-1.45)	0.83 (0.68-1.01)	1.06 (0.87-1.29)
Minimum 10 locations	0.70 (0.45-1.07)	0.76 (0.49-1.17)	0.32 (0.17-0.61)	<b>0.36</b> <b>(0.19-0.68)</b>	0.57 (0.34-0.98)	0.64 (0.37-1.10)	0.64 (0.35-1.19)	0.67 (0.35-1.40)	0.62 (0.31-1.23)	0.70 (0.35-1.40)	0.61 (0.39-0.95)	0.67 (0.42-1.06)

Abbreviations: CI, Confidence Interval; MSK, Musculoskeletal; OR, Odds Ratio; PA, Physical Activity; WHO, World Health Organization

Footnote: A group of participants who did not meet the WHO recommendations of PA (i.e. PA less than 150 min per week) was set as the reference group. The model was adjusted for sex, age, employment status, and depression risk.



**STROBE 2007 (v4) Statement—Checklist of items that should be included in reports of *cross-sectional studies***

Section/Topic	Item #	Recommendation	Reported on page #
<b>Title and abstract</b>	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1-3
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	1-3
<b>Introduction</b>			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	3-4
Objectives	3	State specific objectives, including any prespecified hypotheses	3-4
<b>Methods</b>			
Study design	4	Present key elements of study design early in the paper	4
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	4-5
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants	5
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	5-6
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	5-6
Bias	9	Describe any efforts to address potential sources of bias	5-6
Study size	10	Explain how the study size was arrived at	5-6
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	5-6
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	5-6
		(b) Describe any methods used to examine subgroups and interactions	5-6
		(c) Explain how missing data were addressed	5-6
		(d) If applicable, describe analytical methods taking account of sampling strategy	N/A
		(e) Describe any sensitivity analyses	N/A
<b>Results</b>			



Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	6
		(b) Give reasons for non-participation at each stage	N/A
		(c) Consider use of a flow diagram	N/A
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	6
		(b) Indicate number of participants with missing data for each variable of interest	N/A
Outcome data	15*	Report numbers of outcome events or summary measures	7
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	7-8
		(b) Report category boundaries when continuous variables were categorized	7-8
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	N/A
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	N/A
<b>Discussion</b>			
Key results	18	Summarise key results with reference to study objectives	8-12
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	12
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	11-12
Generalisability	21	Discuss the generalisability (external validity) of the study results	11-12
<b>Other information</b>			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	13

\*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at [www.strobe-statement.org](http://www.strobe-statement.org).

# BMJ Open

## Association between physical activity and musculoskeletal pain: an analysis of international data from the ASAP survey

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-059525.R1
Article Type:	Original research
Date Submitted by the Author:	16-May-2022
Complete List of Authors:	Rhim, Hye Chang; Metrowest Medical Center Tenforde, Adam; Harvard Medical School, Department of Physical Medicine and Rehabilitation; Spaulding Rehabilitation Hospital Mohr, Lisa; Goethe University Frankfurt, Department of Sports Medicine Hollander, Karsten; MSH Medical School Hamburg, Institute of Interdisciplinary Exercise Science and Sports Medicine Vogt, Lutz; Goethe-Universität Frankfurt am Main, Department of Sports Medicine Groneberg, David; Goethe University Frankfurt, Institute of Occupational Medicine, Social Medicine and Environmental Medicine Wilke, Jan; Goethe University Frankfurt, Institute of Occupational Medicine, Social Medicine and Environmental Medicine
<b>Primary Subject Heading</b>:	Sports and exercise medicine
Secondary Subject Heading:	Epidemiology, Public health, Sports and exercise medicine, Rehabilitation medicine, Rheumatology
Keywords:	SPORTS MEDICINE, REHABILITATION MEDICINE, Musculoskeletal disorders < ORTHOPAEDIC & TRAUMA SURGERY, PAIN MANAGEMENT

SCHOLARONE™  
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1  
2  
3 **Association between physical activity and musculoskeletal pain: an**  
4  
5  
6 **analysis of international data from the ASAP survey**  
7

8  
9 Hye Chang Rhim\*, Adam Tenforde\*, Lisa Mohr, Karsten Hollander, Lutz Vogt, David A.  
10  
11 Groneberg, Jan Wilke†

12  
13 \* The first two authors equally contributed to this work  
14  
15

16  
17  
18 Hye Chang Rhim, MetroWest Medical Center, Tufts University School of Medicine,  
19 Framingham, MA, USA

20  
21 Adam Tenforde, Department of Physical Medicine and Rehabilitation, Harvard Medical  
22 School/Spaulding Rehabilitation Hospital, Boston, MA, USA

23  
24 Lisa Mohr, Department of Sports Medicine, Goethe University Frankfurt, Frankfurt, Germany

25  
26 Karsten Hollander, Institute of Interdisciplinary Exercise Science and Sports Medicine, Medical  
27 School Hamburg, Hamburg, Germany

28  
29 Lutz Vogt, Department of Sports Medicine, Goethe University Frankfurt, Frankfurt, Germany

30  
31 David A. Groneberg, Institute of Occupational, Social, and Environmental Medicine, Goethe  
32 University, Frankfurt, Germany

33  
34 Jan Wilke, Institute of Occupational, Social, and Environmental Medicine, Goethe University,  
35 Frankfurt, Germany

36  
37  
38  
39 † Corresponding author: Jan Wilke, Institute of Occupational, Social, and Environmental  
40 Medicine, Goethe University, , Frankfurt, Germany, Email: [wilke@sport.uni-frankfurt.de](mailto:wilke@sport.uni-frankfurt.de)  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## ABSTRACT

**Objective:** To investigate the association of physical activity (PA) with musculoskeletal pain (MSK-pain).

**Design:** Cross-sectional study

**Setting:** 14 countries (Argentina, Australia, Austria, Brazil, Chile, France, Germany, Italy, the Netherlands, Singapore, South Africa, Spain, Switzerland, and the United States of America)

**Participants:** Individuals aged 18 or older living in participating countries.

**Primary and secondary outcome measures:** PA volumes were assessed with an adapted version of the Nordic Physical Activity Questionnaire-short (NPAQ-short). Prevalence of MSK-pain was captured by means of a 20-item checklist of body locations. Based on the WHO recommendation on PA, participants were classified as non-compliers (0-150 min/week), compliers (150-300 min/week), double compliers (300-450 min/week), triple compliers (450-600 min/week), quadruple compliers (600-750 min/week), quintuple compliers (750-900 min/week), and top compliers (more than 900 min/week). Multivariate logistic regression was used to obtain adjusted odds ratios of the association between PA and MSK-pain for each body location, correcting for age, sex, employment status, and depression risk.

**Results:** A total of 13,741 participants completed the survey. Compared to non-compliers, compliers had smaller odds of MSK-pain in one location (thoracic pain, OR 0.77, CI 0.64-0.93). Double compliance was associated with reduced pain occurrence in six locations (elbow, OR 0.70, CI 0.50-0.98; forearm, OR 0.63, CI 0.40-0.99; wrist, OR 0.74, CI 0.57-0.98; hand, OR 0.57, CI 0.40-0.79; fingers, OR 0.72, CI 0.52-0.99; abdomen, OR 0.61, CI 0.41-0.91). Triple to top compliance was also linked with lower odds of MSK-pain (five locations in triple compliance, three in quadruple compliance, two in quintuple compliance, three in top compliance), but, at the same time, presented increased odds of MSK-pain in some of the other locations.

**Conclusion:** A dose of 300-450 min WHO-equivalent PA/week was associated with reduced MSK-pain. On the other hand, excessive doses of PA were associated with increased pain in certain body locations.

### Strengths and Limitations of this study

- This is the first large-scale analysis of associations between MSK pain and PA considering multiple anatomical locations
- Large sample size enabled to investigate the associations between different degrees of compliance to physical activity recommended by WHO and MSK-pain
- Administration of the survey in 14 countries allowed participation of diverse populations
- Self-reported data may be subject to recall bias
- Cross-sectional observational design prohibits causal inference

For peer review only

## INTRODUCTION

Musculoskeletal pain (MSK-pain) is a common condition that can have negative physical, psychological, and social impacts.<sup>1</sup> A summary of previous epidemiological studies conducted with diverse techniques and populations revealed that MSK-pain affects between 13.5% and 47% of the general population with prevalence higher in women and increasing strongly with age.<sup>2</sup> Musculoskeletal conditions contribute to disability, especially in older age groups.<sup>2</sup> It has been reported that disability-adjusted life-years (DALYs), which reflects the years of life lost due to premature mortality and years of life lived with disability, increased by 62% between 1990 and 2016 around the world with 20% surge during the ten-year interval from 2006 to 2016.<sup>3</sup> Most of the increased burden has derived from disability due to increased aging population affected by MSK conditions, and the burden of MSK disorders is expected to increase even more in the future.<sup>4</sup>

Achieving sufficient physical activity (PA) is associated with a variety of positive health outcomes such as substantial risk reduction in all-cause mortality<sup>5</sup> as well as multiple chronic diseases including type 2 diabetes and metabolic syndrome,<sup>6</sup> cancer,<sup>6</sup> and cardiovascular disease.<sup>7</sup> In the light of these positive impacts, World Health Organization (WHO) recommends 150-300 min of moderate-intensity PA, or 75-150 min of vigorous-intensity PA, or aerobic PA with some combination of moderate and vigorous intensities.<sup>8</sup> PA is also considered one of the most important strategies to prevent and manage MSK pain.<sup>9</sup> However, compared to the number of studies investigating the association of PA with non-communicable disease, there seems to be a literature gap regarding MSK-pain. Furthermore, it is still less clear whether the amounts recommended by WHO are sufficient to elicit benefits in terms of addressing MSK-pain. The few available studies examining the relation of regular PA and MSK-pain tended to focus on

1  
2  
3 influence of PA for specific body locations or specific diagnoses such as low back pain, neck  
4 pain, or osteoarthritis and found inconsistent results.<sup>10</sup> Other studies have evaluated the  
5  
6 associations between PA and pain in occupational settings such as among physical therapists or  
7  
8 teaching staff.<sup>11 12</sup> Particularly, the interplay between the volume of PA and MSK-pain within the  
9  
10 general population has been less explored.  
11  
12  
13

14  
15 The purpose of this study was to investigate the association of total PA with MSK-pain in  
16  
17 a variety of anatomical locations including both upper and lower extremities. We hypothesize  
18  
19 that greater time spent in PA than WHO recommendation would be associated with reduction of  
20  
21 MSK-pain, but excess time performing PA might be associated with higher MSK-pain.  
22  
23  
24  
25

## 26 **METHODS**

### 27 *Study Design*

28  
29  
30 This article presents an explorative analysis of pre-pandemic baseline data on PA and  
31  
32 MSK-pain assessed during the ASAP (Activity and Health during the SARS-CoV-2 Pandemic)  
33  
34 survey. The survey was administered with results collected between April 3 and May 9, 2020,  
35  
36 including participants from 14 countries (Argentina, Australia, Austria, Brazil, Chile, France,  
37  
38 Germany, Italy, the Netherlands, Singapore, South Africa, Spain, Switzerland, and the United  
39  
40 States of America (USA)).<sup>13-16</sup> Ethical approval was obtained from the ethics committees of the  
41  
42 study center and collaborating institutions. All participants provided digital informed consent.  
43  
44  
45  
46  
47  
48

### 49 *Participants*

50  
51 Eligibility for participation in the ASAP survey was limited to individuals aged 18 or  
52  
53 older living in participating countries. Recruitment was performed online using promotion by  
54  
55  
56  
57



1  
2  
3 health-related organizations, mailing lists, and social media advertising (e.g. Facebook,  
4  
5 Instagram, Twitter).  
6  
7  
8  
9

### 10 *Questionnaire*

11  
12 To capture PA, the ASAP survey incorporated an adapted version of the Nordic Physical  
13 Activity Questionnaire-short (NPAQ-short). The instrument retrospectively assessed the  
14 amounts of moderate and combined moderate and vigorous activities (min/week) during leisure  
15 and occupational time. Moderate activities were defined as those that increase heart rate or  
16 breathing, and vigorous activities were defined as those that make heart racing, sweating, and  
17 shortness of breath. The questionnaire asked how much time participants spent in total on both  
18 moderate and vigorous PA on a typical week, and the time spent in all activities with a minimal  
19 duration of 10 minutes was asked to be added and entered in the form. The NPAQ-short has been  
20 shown to be reliable (test-retest reliability:  $\rho = 0.80$  to  $0.82$ ) and valid for observing  
21 compliance with the WHO recommendations on PA.<sup>17</sup> The questionnaire was available in 7  
22 different languages (Dutch, English, German, French, Italian, Brazilian-Portuguese, Spanish),  
23 and clarity and comprehensibility were validated by native speakers through forward and  
24 backward translation.  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41

42 Prevalence of MSK-pain was captured by means of binary responses (yes/no) to an  
43 adapted 20-item checklist from a consensus statement on epidemiological injury reporting.<sup>18</sup>  
44 Body locations were categorized as follows: neck/cervical spine, shoulder, upper arm, elbow,  
45 forearm, wrist, hand, fingers, thoracic spine, ribs, lower back, abdomen, pelvis/gluteal, hip,  
46 groin, thigh, knee, lower leg, ankle/Achilles tendon, foot/toe.  
47  
48  
49  
50  
51  
52

53 The English version of the ASAP survey can be found in Supplemental File 1.  
54  
55  
56  
57

### *Data Processing and Statistical Analysis*

Self-reported PA was categorized as multiples of compliance with WHO guidelines which recommend 150-300 minutes/week of moderate activity, 75-150 minutes/week of vigorous activity, or any adequate combination of both.<sup>8</sup> We used the formula (minutes of moderate-to-vigorous PA – minutes of vigorous PA) + minutes of vigorous PA \*2 to classify participants as non-compliers (0-150 min/week), compliers (150-300 min/week), double compliers (300-450 min/week), triple compliers (450-600 min/week), quadruple compliers (600-750 min/week), quintuple compliers (750-900 min/week), and top compliers (more than 900 min/week).

For each body region, univariate logistic regression was conducted to calculate the unadjusted odds ratio (OR) of the association between pain (dependent variable) and PA. In a similar way, univariate logistic regression was then used to identify associations of pain (dependent variable) and potential confounding variables (sex, age, employment status, depression risk). Finally, multivariate logistic regression was performed including these confounding variables (if relevant) to obtain the adjusted ORs and 95% confidence interval (CI) of the association between the volume of PA and pain. All data analyses were conducted using SPSS 22 (SPSS INC., Armonk, NY, USA), and the significance level was set to  $\alpha = 0.05$ .

### *Patient and Public Involvement*

Members of the target population without medical background were involved in the designing phase of the ASAP questionnaire. The questionnaire was face validated for each

1  
2  
3 language with five non-academic individuals. Feedback on comprehension and clarity of the  
4  
5 wording was used.  
6  
7  
8  
9

## 10 **RESULTS**

11  
12 Valid datasets were identified for 13,741 participants ( $38 \pm 15$  years, minimum 18 and  
13  
14 maximum 100, 59% females). The demographic data are summarized in the Table 1. 2604  
15  
16 individuals did not meet the WHO recommendation of PA while  $n=2735$  belonged to 150-300  
17  
18 min group,  $n=1957$  to 300-450 min group,  $n=1749$  to 450-600 min group,  $n=1066$  to 600-750  
19  
20 min group,  $n=849$  to 750-900 min group, and  $n=2781$  to 900+ min group. Comprehensive  
21  
22 results are summarized in the Table 2 and 3.  
23  
24  
25

26 Compared to inactive individuals, simple compliance was associated with reduced MSK-  
27  
28 pain in one body location (thoracic pain, OR 0.77, CI 0.64-0.93 Table 1). Double compliance  
29  
30 increased the number of locations with less pain to six (elbow, OR 0.70, CI 0.50-0.98; forearm,  
31  
32 OR 0.63, CI 0.40-0.99; wrist, OR 0.74, CI 0.7-0.98; hand, OR 0.57, CI 0.40-0.79; fingers, OR  
33  
34 0.72, CI 0.52-0.99; abdomen, OR 0.61, CI 0.41-0.91). Although higher amounts of PA were  
35  
36 linked to lower pain levels to a variable degree (five body locations in triple compliance, three in  
37  
38 quadruple compliance, two in quintuple compliance, three in top compliance), they also showed  
39  
40 increased pain in other locations. Specifically, triple compliance was associated with higher pain  
41  
42 in thigh (OR 1.41, CI 1.03-1.92), knee (OR 1.25, CI 1.06-1.50), and ankle/Achilles tendon (OR  
43  
44 1.47, CI 1.14-1.88). Quadruple compliance increased pain locations to four, quintuple  
45  
46 compliance to six, and top compliance to seven.  
47  
48  
49  
50

51 Triple compliance was associated with lower odds to have a total of 5 or more (OR 0.75,  
52  
53 CI 0.60-0.95) or 10 or more (OR 0.36, CI 0.19-0.68) pain locations, and quadruple compliance  
54  
55  
56  
57

1  
2  
3 was associated with lower odds to have 5 or more pain locations (OR 0.73, CI 0.57-0.93).

4  
5 However, quintuple and top compliances were associated with higher odds of having a minimum  
6  
7 one pain location (OR 1.28, CI 1.10-1.51 and 1.30, CI 1.16-1.45 respectively).  
8  
9

## 10 11 12 **DISCUSSION**

13  
14  
15 The purpose of the present study was to understand the relation between PA and MSK-  
16  
17 pain. Previous research focused on the impact of PA on specific locations of MSK-pain (e.g.,  
18  
19 low back and neck<sup>19</sup>) or certain occupational settings.<sup>11 12</sup> Our large-scale multinational study is  
20  
21 novel in that it identified the associations between different degrees of compliance to PA  
22  
23 recommended by WHO and multiple body locations in the general population after adjusting for  
24  
25 multiple cofounding factors including age, which is known to be positively associated with  
26  
27 MSK-pain prevalence.  
28  
29

30  
31 Guideline compliance (150-300 min per week) was weakly associated with MSK pain, showing  
32  
33 lower odds of having pain only in thoracic spine but higher odds in foot/toes. In contrast, double  
34  
35 compliance (300-450 min per week) substantially increased the number of beneficial  
36  
37 associations to six and thus seems to represent the optimal dose when PA is undertaken to  
38  
39 prevent MSK. Finally, higher levels of PA (triple to top compliance) were associated with less  
40  
41 odds of having pain in multiple upper body locations but paradoxically contributed to higher  
42  
43 odds of lower extremity pain. Notably, participating in 300-600 min of PA per week was  
44  
45 associated with lower odds of having pain in upper extremities, neck, and thoracic and lumbar  
46  
47 spine. In contrast, participating in greater than 450 min of PA per week was associated with  
48  
49 higher odds of having pain in the lower extremity.  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

### *Time spent in PA and pain in neck, back, and upper extremity*

A previous systematic review showed that there was limited evidence for no association between PA and neck pain.<sup>19</sup> However, our study found that participating in PA between 450-900+ min was associated with lower odds of having pain in neck/cervical spine. Several epidemiological studies have demonstrated that certain postures sustained for prolonged duration combined with sedentary lifestyle were associated with neck pain.<sup>20-22</sup> Therefore, increased PA levels may be helpful to consider in those at risk for neck pain.

Association between PA and thoracic spine has been less explored,<sup>23</sup> but a recent observational study found that PA less than 150 min per week was associated with reduced thoracic mobility.<sup>24</sup> Our findings build on previous research in that PA less than 150 min per week is also associated with higher odds of having pain in the thoracic spine.

While it is generally accepted that PA and exercise are beneficial in the management of acute and chronic low back pain, a previous systematic review could not identify either positive or negative relationship.<sup>25</sup> One study suggested that the relationship between the level of activity and back pain might be explained by a U-shaped curve that suggests both low and excessive PA may increase the risk of low back pain.<sup>26</sup> Our findings partly support this concept as PA of 450-750 min was associated with lower odds of low back pain while lower or higher PA than that range did not have significant association.

PA in the range of 300-600 min was also associated with lower odds of having pain in several locations in the upper extremity such as elbow, forearm, wrist, hand, and fingers. PA exceeding 750 min was associated with higher odds of shoulder pain. The underlying mechanisms of how PA modulates pain are not completely understood, but several pathways have been proposed. Animal study findings suggest regular PA may act on the central nervous

1  
2  
3 system (CNS) and alter rate of pain hypersensitivity, dysregulation of pain modulation, and  
4 development of chronic pain.<sup>27-29</sup> In humans, it has been proposed that PA may intervene  
5 excitability and inhibition in the CNS,<sup>30-32</sup> and anti-inflammatory and antioxidant effects of  
6 regular PA might diminish the processes contributing to central sensitization.<sup>33-35</sup> Other proposed  
7 mechanisms in humans include the activation of opioid and serotonin pathways<sup>36</sup> or involvement  
8 of endocannabinoid system<sup>37</sup> induced from regular PA which could exert analgesic effects.  
9  
10 While further research is needed to elucidate how much and what type of PA can induce such  
11 changes to modulate pain, our results suggest that PA between 300-600 mins per week may be  
12 sufficient for spinal conditions and upper extremity pain, with PA exceeding 750 min associated  
13 with higher likelihood of shoulder pain.  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27

### 28 *Association of PA and lower extremity pain*

29  
30  
31 The association of PA to lower extremity pain was different than what was observed for  
32 upper extremity and spine conditions. Our results suggest PA exceeding 450 min was associated  
33 with higher odds of MSK-pain in lower extremity. These findings may be partially explained by  
34 higher amounts of PA are likely to involve greater use of the lower extremity. In the United  
35 States, it has been reported that walking is the most popular form of exercise followed by biking,  
36 yard work, strength training, dancing, and running, which are activities that commonly place  
37 physical demands through the lower extremity.<sup>38</sup> Running is one of the most popular exercises in  
38 the world and has been shown to result in lower extremity pain in multiple anatomical locations  
39 with nearly all (94.7% of runners) reporting experience of pain at least once after running.<sup>39</sup>  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50

51 We also observed that greater PA was associated with a higher number of sites of MSK-  
52 pain in the lower extremity. A dose response was observed: 450-600 min was associated with  
53  
54  
55  
56  
57

1  
2  
3 pain in three anatomical regions, 600-750 min with pain in four anatomical regions, 750-900 min  
4  
5 with five anatomical regions, and 900+ min with six anatomical regions. The optimal PA level to  
6  
7 reduce pain in those with existing musculoskeletal lower extremity pain is unknown. A prior  
8  
9 study reported that a minimum of 45 total moderate-vigorous min per week was sufficient to  
10  
11 elicit improved or sustained high function with lower-extremity symptoms regardless of age,  
12  
13 gender, body mass index, or presence of knee osteoarthritis.<sup>40</sup> Our findings of PA ranging from  
14  
15 150-450 min not increasing the odds of having pain in the lower extremities suggest this range  
16  
17 might be appropriate to be safe and promote other health benefits.  
18  
19  
20  
21  
22  
23

#### 24 *Clinical implication*

25  
26 While the WHO 2020 guidelines on PA recommend 150-300 min of moderate-intensity  
27  
28 PA, or 75-150 min of vigorous-intensity PA, or some equivalent combination of moderate-  
29  
30 intensity and vigorous-intensity aerobic PA per week for optimal health outcomes,<sup>8</sup> the current  
31  
32 study suggests that more PA beyond the WHO recommendation may be necessary to decrease  
33  
34 the odds of having pain particularly in the upper extremity. Our findings suggest a target of 300-  
35  
36 450 min of PA per week could be optimal for preventing pain in the upper extremity without  
37  
38 clear associated higher rate of lower extremity pain. Also, this range was associated with lower  
39  
40 odds of having pain in multiple number of locations. Recognizing concerns on higher prevalence  
41  
42 of pain in low back, neck, and thoracic spine increased during the COVID-19 pandemic,<sup>15</sup> PA  
43  
44 target of the higher target of 450 min of weekly exercise may be helpful in this population. Our  
45  
46 results suggest exceeding 450 min of PA may not be advisable for those with increased concern  
47  
48 for lower extremity pain. Furthermore, PA above 750 minutes was associated with having at  
49  
50 least one pain location.  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

### *Limitation*

While our findings derived from a large-scale multinational study of participants, we do note potential limitations. Self-report of PA and MSK-pain are limited by reporting bias and inaccuracy including risk for over-reporting level of PA.<sup>41 42</sup> The cross-sectional study design limits our understanding between PA and the etiology of MSK-pain. Also, we are limited in ability in discriminating the types of PA to report of MSK-pain by anatomical locations. We were not able to distinguish or identify bilateral MSK-pain from our questionnaire as well. Furthermore, because a separate analysis was run for each body region, there is a risk of multiple testing problem. Since our analysis was explorative in nature, further prospective cohort or interventional studies are needed to elucidate the best form and dose of PA to address MSK-pain by anatomical location and specific musculoskeletal injury, and additionally investigate the role of MSK-pain intensity instead of using a binary (yes/no) classification.

### **CONCLUSION**

Our findings showed that PA time above the WHO recommendations was associated with lower odds of having pain in multiple locations such as neck, thoracic spine, low back, and in the upper extremities. Especially, undertaking PA for 300-450 min per week was associated with reduced pain occurrence in six locations, elbow, forearm, wrist, hand, fingers, and abdomen.

**Acknowledgment:** The authors acknowledge the valuable help from the following authors with promoting ASAP survey for data collection (in alphabetical order): Benedict Tan, Bernhard Novak, Celso Ramírez, Chiara Fossati, Christoph Heidt, Daniel E. Lieberman, David Jimenez-Pavon, Evert Verhagen, Fabio Pigozzi, Falk Richter, Fernando Laiño, Johannes Jaunig, Julian David Pillay, Luiz Carlos Hespanhol Junior, Marcela González-Gross, Matteo Sattler, Mireille van Poppel, Pascal Edouard, Steffen Willwacher

**Funding:** This research received no external funding.



1  
2  
3 **Data Availability Statement:** Data are available upon reasonable request  
4

5 **Ethics Statements**  
6

7 -Ethics approval: This study was approved by the University of Queensland Health and  
8 Behavioural Sciences, Low & Negligible Risk Ethics Sub-Committee, Ethics Committee of Karl  
9 Franzens University Graz, Research Ethics Committee of Fundación Instituto Superior de  
10 Ciencias de la Salud, Research Ethics Committee of the Universidade Cidade de São Paulo,  
11 Institutional Ethics Committee of the University of Santiago de Chile, Saint-Etienne University  
12 Hospital Ethical Committee, Ethics Committee of the Faculty of Psychology and Sports Sciences  
13 of Goethe University, Comitato di Ateneo per la Ricerca, Università degli Studi di Roma “Foro  
14 Italico”, Medical Ethical Committee of Amsterdam UMC, Institutional Research Ethics  
15 Committee of Durban University of Technology, SingHealth Centralised Institutional Review  
16 Board, Cantonal Ethics Committee Northwest Switzerland, Ethics Committee of Universidad  
17 Politécnica de Madrid, and Partners Human Research Committee  
18  
19

20  
21 -Digital informed consent was obtained from all subjects involved in the study.  
22

23 **Authors Contribution:** HCR/AT: data collection, interpretation, drafting and critical revision of  
24 the manuscript, LM, KH, LV, DG: data collection, critical revision of the manuscript, JW:  
25 conception/design, data collection, interpretation, critical revision of the manuscript  
26

27 Competing interests: None declared.  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## REFERENCES

1. Paananen M, Taimela S, Auvinen J, et al. Impact of self-reported musculoskeletal pain on health-related quality of life among young adults. *Pain Med* 2011;12(1):9-17.
2. Cimmino MA, Ferrone C, Cutolo M. Epidemiology of chronic musculoskeletal pain. *Best Pract Res Clin Rheumatol* 2011;25(2):173-83.
3. Collaborators GDaH. Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet* 2017;390(10100):1260-344. doi: 10.1016/s0140-6736(17)32130-x [published Online First: 2017/09/19]
4. Smith E, Hoy DG, Cross M, et al. The global burden of other musculoskeletal disorders: estimates from the Global Burden of Disease 2010 study. *Ann Rheum Dis* 2014;73(8):1462-9. doi: 10.1136/annrheumdis-2013-204680 [published Online First: 2014/03/05]
5. Ekelund U, Tarp J, Steene-Johannessen J, et al. Dose-response associations between accelerometry measured physical activity and sedentary time and all cause mortality: systematic review and harmonised meta-analysis. *BMJ* 2019;366
6. Lee I-M, Shiroma EJ, Lobelo F, et al. Effect of physical inactivity on major non-communicable diseases worldwide: an analysis of burden of disease and life expectancy. *Lancet* 2012;380(9838):219-29.
7. Kyu HH, Bachman VF, Alexander LT, et al. Physical activity and risk of breast cancer, colon cancer, diabetes, ischemic heart disease, and ischemic stroke events: systematic review and dose-response meta-analysis for the Global Burden of Disease Study 2013. *BMJ* 2016;354
8. Bull FC, Al-Ansari SS, Biddle S, et al. World Health Organization 2020 guidelines on physical activity and sedentary behaviour. *Br J Sports Med* 2020;54(24):1451-62.
9. Lin I, Wiles L, Waller R, et al. Patient-centred care: the cornerstone for high-value musculoskeletal pain management. *Br J Sports Med* 2020;54(21):1240-42. doi: 10.1136/bjsports-2019-101918 [published Online First: 2020/06/27]
10. Geneen LJ, Moore RA, Clarke C, et al. Physical activity and exercise for chronic pain in adults: an overview of Cochrane Reviews. *Cochrane Database Syst Rev* 2017(4)
11. Ezzatvar Y, Calatayud J, Andersen L, et al. Are moderate and vigorous leisure-time physical activity associated with musculoskeletal pain? a cross-sectional study among 981 physical therapists. *Am J Health Promot* 2020;34(1):67-70.
12. Tami AM, Bika Lele EC, Mekoulou Ndongo J, et al. Epidemiology of Musculoskeletal Disorders among the Teaching Staff of the University of Douala, Cameroon: Association with Physical Activity Practice. *Int J Environ Res Public Health* 2021;18(11):6004.
13. Wilke J, Mohr L, Tenforde AS, et al. Activity and health during the SARS-CoV2 pandemic (ASAP): study protocol for a multi-national network trial. *Front Med* 2020;7:302.
14. Wilke J, Mohr L, Tenforde AS, et al. Restrictercise! Preferences regarding digital home training programs during confinements associated with the COVID-19 pandemic. *Int J Environ Res Public Health* 2020;17(18):6515.
15. Wilke J, Mohr L, Tenforde AS, et al. A pandemic within the pandemic? Physical activity levels substantially decreased in countries affected by COVID-19. *Int J Environ Res Public Health* 2021;18(5):2235.
16. Wilke J, Hollander K, Mohr L, et al. Drastic reductions in mental well-being observed globally during the COVID-19 pandemic: results from the ASAP survey. *Front Med* 2021;8:246.

17. Danquah IH, Petersen CB, Skov SS, et al. Validation of the NPAQ-short—a brief questionnaire to monitor physical activity and compliance with the WHO recommendations. *BMC Public Health* 2018;18(1):1-10.
18. Bahr R, Clarsen B, Derman W, et al. International Olympic Committee consensus statement: methods for recording and reporting of epidemiological data on injury and illness in sports 2020 (including the STROBE extension for sports injury and illness surveillance (STROBE-SIIS)). *Orthop J Sports Med* 2020;8(2):2325967120902908.
19. Sitthipornvorakul E, Janwantanakul P, Purepong N, et al. The association between physical activity and neck and low back pain: a systematic review. *Eur Spine J* 2011;20(5):677-89.
20. Ortiz-Hernández L, Tamez-González S, Martínez-Alcántara S, et al. Computer use increases the risk of musculoskeletal disorders among newspaper office workers. *Arch Med Res* 2003;34(4):331-42.
21. Janwantanakul P, Pensri P, Jiamjarasrangsi W, et al. Associations between prevalence of self-reported musculoskeletal symptoms of the spine and biopsychosocial factors among office workers. *J Occup Health* 2009:0901270054-54.
22. Cagnie B, Danneels L, Van Tiggelen D, et al. Individual and work related risk factors for neck pain among office workers: a cross sectional study. *Eur Spine J* 2007;16(5):679-86.
23. Briggs AM, Smith AJ, Straker LM, et al. Thoracic spine pain in the general population: prevalence, incidence and associated factors in children, adolescents and adults. A systematic review. *BMC Musculoskelet Disord* 2009;10(1):1-12.
24. Heneghan NR, Baker G, Thomas K, et al. What is the effect of prolonged sitting and physical activity on thoracic spine mobility? An observational study of young adults in a UK university setting. *BMJ Open* 2018;8(5):e019371.
25. Hendrick P, Milosavljevic S, Hale L, et al. The relationship between physical activity and low back pain outcomes: a systematic review of observational studies. *Eur Spine J* 2011;20(3):464-74.
26. Heneweer H, Vanhees L, Picavet HSJ. Physical activity and low back pain: a U-shaped relation? *Pain* 2009;143(1-2):21-25.
27. Bobinski F, Ferreira TAA, Córdova MM, et al. Role of brainstem serotonin in analgesia produced by low-intensity exercise on neuropathic pain following sciatic nerve injury in mice. *Pain* 2015;156(12):2595.
28. Sluka KA, O'Donnell JM, Danielson J, et al. Regular physical activity prevents development of chronic pain and activation of central neurons. *J Appl Physiol* 2013;114(6):725-33.
29. Stagg NJ, Mata HP, Ibrahim MM, et al. Regular exercise reverses sensory hypersensitivity in a rat neuropathic pain model: role of endogenous opioids. *Anesthesiology* 2011;114(4):940-48.
30. Geva N, Defrin R. Enhanced pain modulation among triathletes: a possible explanation for their exceptional capabilities. *Pain* 2013;154(11):2317-23.
31. Naugle KM, Ohlman T, Naugle KE, et al. Physical activity behavior predicts endogenous pain modulation in older adults. *Pain* 2017;158(3):383-90.
32. Naugle KM, Riley JL. Self-reported physical activity predicts pain inhibitory and facilitatory function. *Med Sci Sports Exerc* 2014;46(3):622.
33. Radak Z, Chung HY, Koltai E, et al. Exercise, oxidative stress and hormesis. *Ageing Res Rev* 2008;7(1):34-42.
34. Woods JA, Wilund KR, Martin SA, et al. Exercise, inflammation and aging. *Aging Dis* 2012;3(1):130.
35. Dhondt E, Danneels L, Van Oosterwijck S, et al. The influence of physical activity on the nociceptive flexion reflex in healthy people. *Eur J Pain* 2021;25(4):774-89.
36. Tour J, Löfgren M, Mannerkorpi K, et al. Gene-to-gene interactions regulate endogenous pain modulation in fibromyalgia patients and healthy controls-antagonistic effects between opioid and serotonin-related genes. *Pain* 2017;158(7):1194-203. doi: 10.1097/j.pain.0000000000000896 [published Online First: 2017/03/11]

- 1  
2  
3 37. Tantimonaco M, Ceci R, Sabatini S, et al. Physical activity and the endocannabinoid system: an  
4 overview. *Cell Mol Life Sci* 2014;71(14):2681-98.  
5  
6 38. Ham SA, Kruger J, Tudor-Locke C. Participation by US adults in sports, exercise, and recreational  
7 physical activities. *J Phys Act Health* 2009;6(1):6-14.  
8  
9 39. Rhim HC, Kim SJ, Jeon JS, et al. Prevalence and risk factors of running-related injuries in Korean non-  
10 elite runners: a cross-sectional survey study. *J Sports Med Phys Fitness* 2021;61(3):413-19. doi:  
11 10.23736/s0022-4707.20.11223-4 [published Online First: 2020/08/04]  
12  
13 40. Dunlop DD, Song J, Lee J, et al. Physical activity minimum threshold predicting improved function in  
14 adults with Lower-Extremity symptoms. *Arthritis Care Res* 2017;69(4):475-83.  
15  
16 41. Valanou E, Bamia C, Trichopoulou A. Methodology of physical-activity and energy-expenditure  
17 assessment: a review. *J Public Health* 2006;14(2):58-65.  
18  
19 42. Schmier J, Halpern M. Patient recall and recall bias of health state and health status. *Expert Rev*  
20 *Pharmacoecon Outcomes Res.* 2004; 4 (2): 159–63.  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Table 1. Demographic data of the participants by countries**

Country	ARG	AUS	AUT	BRA	CHE	CHL	DEU	ESP	FRA	ITA	NLD	SGP	USA	ZAF	Others	Total
<b>Sex (M/F)</b>	429/494	56/248	192/546	620/948	115/212	471/766	696/1356	310/277	1200/1046	348/453	50/129	437/434	364/711	236/293	108/122	5632/8035
<b>Age (SD)</b>	37.1 (15.4)	41.6 (14.1)	27.3 (9.6)	34.2 (10.6)	37.3 (11.5)	31.5 (13.6)	40.4 (16.3)	43.0 (13.4)	43.3 (16.9)	38.5 (15.3)	47.5 (14.0)	40.1 (12.1)	43.1 (14.0)	32.4 (14.3)	40.0 (13.5)	38.3 (15.1)
<b>WHO-5 (SD)</b>	54.3 (17.8)	50.1 (14.8)	55.0 (16.5)	53.0 (16.0)	50.4 (15.2)	54.7 (18.2)	52.9 (17.0)	49.2 (15.8)	48.3 (14.8)	56.3 (17.3)	49.0 (14.7)	52.2 (17.6)	49.4 (14.9)	52.2 (21.1)	51.2 (17.2)	52.0 (16.8)
<b>Employment (Yes, %)</b>	61.9	86.8	62.7	78.8	96.0	59.2	73.2	79.8	69.9	65.9%	77.1	88.8	84.1	53.7	85.0	72.8
<b>MVPA (SD)</b>	488.7 (596.2)	352.3 (340.0)	384.6 (408.7)	396.4 (454.9)	379.0 (458.1)	385.7 (518.3)	438.6 (481.3)	493.2 (617.0)	527.9 (516.0)	566.2 (635.3)	506.5 (420.5)	376.5 (445.7)	401.0 (348.0)	310.6 (455.8)	437.8 (529.7)	439.5 (498.7)
<b>VPA (SD)</b>	218.7 (338.0)	121.3 (152.4)	141.4 (206.5)	202.0 (305.7)	130.6 (152.6)	153.9 (287.9)	146.9 (226.5)	188.4 (295.2)	234.7 (343.3)	247.2 (350.1)	200.2 (225.7)	171.0 (302.4)	195.9 (230.0)	144.1 (272.7)	203 (275.6)	186.4 (288.8)

Abbreviations: F, Female; M, Male; MVPA, Moderate to Vigorous Physical Activity; SD, Standard Deviation; VPA, Vigorous Physical Activity, WHO-5, The 5-item World Health Organization Well-Being Index

Country Abbreviations: ARG, Argentina; AUS, Australia; AUT, Austria; BRA, Brazil; CHE, Switzerland; CHL, Chile; DEU, Germany; ESP, Spain; FRA, France; ITA, Italy; NLD, Netherlands; SGP, Singapore; USA, United States of America; ZAF, South Africa

Table 2. Association of PA with MSK-Pain by Anatomical Locations

Location of MSK-Pain	Dose of WHO Guideline-Based PA											
	150-300 min		300-450 min		450-600 min		600-750 min		750-900 min		900+ min	
	Crude OR (95% CI)	Adjusted OR (95% CI)	Crude OR (95% CI)	Adjusted OR (95% CI)	Crude OR (95% CI)	Adjusted OR (95% CI)	Crude OR (95% CI)	Adjusted OR (95% CI)	Crude OR (95% CI)	Adjusted OR (95% CI)	Crude OR (95% CI)	Adjusted OR (95% CI)
Neck/Cervical	0.89 (0.79-1.01)	0.99 (0.87-1.12)	0.76 (0.67-0.88)	0.89 (0.77-1.03)	0.66 (0.57-0.76)	<b>0.78</b> <b>(0.67-0.91)</b>	0.62 (0.52-0.74)	<b>0.75</b> <b>(0.62-0.90)</b>	0.63 (0.52-0.77)	0.82 (0.67-1.00)	0.59 (0.52-0.67)	<b>0.78</b> <b>(0.68-0.89)</b>
Shoulder	0.87 (0.75-1.00)	0.92 (0.79-1.06)	0.87 (0.74-1.02)	0.94 (0.79-1.10)	0.83 (0.71-0.99)	0.93 (0.79-1.11)	0.80 (0.66-0.98)	0.88 (0.72-1.08)	1.10 (0.90-1.34)	<b>1.27</b> <b>(1.04-1.56)</b>	0.98 (0.85-1.13)	<b>1.16</b> <b>(1.00-1.34)</b>
Upper arm	0.77 (0.60-1.00)	0.98 (0.76-1.27)	0.60 (0.44-0.81)	0.81 (0.60-1.11)	0.56 (0.41-0.77)	0.76 (0.54-1.05)	0.62 (0.42-0.89)	0.81 (0.55-1.19)	0.89 (0.63-1.28)	1.23 (0.85-1.80)	0.73 (0.56-0.94)	1.01 (0.77-1.33)
Elbow	0.73 (0.54-0.97)	0.77 (0.57-1.03)	0.64 (0.46-0.89)	<b>0.70</b> <b>(0.50-0.98)</b>	0.95 (0.70-1.30)	0.99 (0.72-1.37)	0.92 (0.64-1.32)	0.93 (0.64-1.37)	0.90 (0.60-1.34)	0.94 (0.62-1.42)	1.19 (0.93-1.53)	1.30 (0.99-1.70)
Forearm	0.91 (0.65-1.28)	1.08 (0.76-1.52)	0.53 (0.34-0.82)	<b>0.63</b> <b>(0.40-0.99)</b>	0.72 (0.47-1.07)	0.85 (0.55-1.30)	0.80 (0.50-1.29)	0.96 (0.59-1.55)	0.74 (0.43-1.26)	0.90 (0.52-1.54)	0.98 (0.70-1.36)	1.17 (0.82-1.65)
Wrist	0.86 (0.70-1.07)	1.07 (0.86-1.34)	0.57 (0.43-0.74)	<b>0.74</b> <b>(0.57-0.98)</b>	0.63 (0.48-0.82)	0.81 (0.62-1.07)	0.79 (0.58-1.06)	1.00 (0.74-1.37)	0.71 (0.50-0.99)	0.95 (0.67-1.34)	0.86 (0.70-1.07)	1.15 (0.91-1.44)
Hand	0.68 (0.53-0.88)	0.81 (0.62-1.05)	0.44 (0.32-0.61)	<b>0.57</b> <b>(0.40-0.79)</b>	0.47 (0.34-0.66)	<b>0.59</b> <b>(0.41-0.83)</b>	0.60 (0.41-0.87)	0.74 (0.50-1.09)	0.60 (0.40-0.91)	0.77 (0.50-1.18)	0.57 (0.44-0.75)	<b>0.74</b> <b>(0.56-0.99)</b>
Fingers	0.85 (0.66-1.10)	0.91 (0.70-1.19)	0.63 (0.46-0.86)	<b>0.72</b> <b>(0.52-0.99)</b>	0.65 (0.47-0.86)	<b>0.71</b> <b>(0.51-0.99)</b>	0.80 (0.56-1.14)	0.93 (0.65-1.34)	0.71 (0.48-1.07)	0.81 (0.53-1.22)	0.75 (0.58-0.98)	0.84 (0.64-1.11)
Thoracic spine	0.75 (0.63-0.90)	<b>0.77</b> <b>(0.64-0.93)</b>	0.83 (0.69-1.02)	0.90 (0.74-1.10)	0.71 (0.58-0.88)	<b>0.78</b> <b>(0.63-0.97)</b>	0.69 (0.54-0.89)	<b>0.74</b> <b>(0.57-0.97)</b>	0.54 (0.40-0.73)	<b>0.64</b> <b>(0.47-0.87)</b>	0.63 (0.52-0.76)	<b>0.77</b> <b>(0.63-0.93)</b>
Ribs	0.85 (0.59-1.21)	0.98 (0.68-1.42)	0.74 (0.49-1.11)	0.88 (0.58-1.34)	0.60 (0.38-0.95)	<b>0.74</b> <b>(0.46-1.17)</b>	1.04 (0.66-1.62)	1.18 (0.73-1.88)	0.69 (0.39-1.22)	0.88 (0.50-1.57)	0.78 (0.54-1.11)	0.90 (0.62-1.36)
Lower back	0.91 (0.80-1.03)	0.93 (0.82-1.06)	0.85 (0.73-0.97)	0.91 (0.78-1.05)	0.77 (0.67-0.90)	<b>0.84</b> <b>(0.72-0.97)</b>	0.69 (0.57-0.82)	<b>0.76</b> <b>(0.63-0.91)</b>	0.85 (0.71-1.03)	0.96 (0.79-1.16)	0.79 (0.70-0.90)	0.93 (0.81-1.06)
Abdomen	0.70 (0.52-0.95)	0.94 (0.69-1.28)	0.45 (0.31-0.67)	<b>0.61</b> <b>(0.41-0.91)</b>	0.68 (0.48-0.97)	0.97 (0.68-1.40)	0.67 (0.44-1.02)	0.89 (0.57-1.37)	0.91 (0.60-1.38)	1.33 (0.87-2.05)	0.60 (0.44-0.83)	0.82 (0.59-1.14)
Pelvis/Gluteals	1.00 (0.78-1.28)	1.11 (0.86-1.43)	0.77 (0.57-1.03)	0.86 (0.64-1.17)	0.92 (0.69-1.23)	1.13 (0.84-1.52)	1.02 (0.74-1.41)	1.15 (0.81-1.62)	0.96 (0.67-1.39)	1.19 (0.82-1.73)	1.10 (0.86-1.40)	<b>1.37</b> <b>(1.06-1.76)</b>
Hip	1.06 (0.87-1.30)	1.05 (0.85-1.29)	0.93 (0.74-1.17)	0.96 (0.76-1.21)	1.05 (0.84-1.32)	1.09 (0.87-1.38)	0.93 (0.71-1.22)	0.97 (0.73-1.29)	1.24 (0.94-1.63)	<b>1.37</b> <b>(1.03-1.81)</b>	0.97 (0.79-1.18)	1.17 (0.95-1.45)
Groin	0.94 (0.65-1.34)	1.04 (0.72-1.49)	0.72 (0.47-1.10)	0.80 (0.52-1.23)	0.98 (0.65-1.46)	1.05 (0.69-1.59)	1.08 (0.69-1.71)	1.20 (0.75-1.91)	1.31 (0.83-2.10)	1.40 (0.87-2.27)	1.28 (0.92-1.79)	1.40 (0.99-1.99)
Thigh	0.99 (0.75-1.31)	1.13 (0.85-1.51)	0.87 (0.63-1.19)	0.99 (0.71-1.38)	1.24 (0.92-1.68)	<b>1.41</b> <b>(1.03-1.92)</b>	1.39 (0.99-1.95)	<b>1.59</b> <b>(1.13-2.25)</b>	1.60 (1.13-2.27)	<b>1.82</b> <b>(1.28-2.61)</b>	1.37 (1.05-1.78)	<b>1.51</b> <b>(1.15-1.99)</b>
Knee	1.02 (0.88-1.19)	1.08 (0.92-1.25)	1.04 (0.88-1.22)	1.10 (0.93-1.30)	1.17 (0.99-1.37)	<b>1.25</b> <b>(1.06-1.50)</b>	1.12 (0.93-1.36)	<b>1.22</b> <b>(1.01-1.49)</b>	1.43 (1.18-1.75)	<b>1.55</b> <b>(1.27-1.90)</b>	1.16 (1.00-1.34)	<b>1.30</b> <b>(1.12-1.51)</b>
Lower leg	0.77 (0.59-1.00)	0.93 (0.71-1.21)	0.82 (0.62-1.07)	1.04 (0.78-1.39)	1.02 (0.77-1.34)	1.31 (0.98-1.73)	1.14 (0.83-1.55)	<b>1.43</b> <b>(1.04-1.97)</b>	0.95 (0.66-1.36)	1.22 (0.85-1.77)	1.03 (0.81-1.31)	<b>1.34</b> <b>(1.04-1.73)</b>
Ankle/Achilles	1.09 (0.87-1.36)	1.14 (0.90-1.43)	1.19 (0.93-1.52)	1.24 (0.96-1.59)	1.42 (1.12-1.81)	<b>1.47</b> <b>(1.14-1.88)</b>	1.48 (1.12-1.94)	<b>1.55</b> <b>(1.17-2.06)</b>	1.70 (1.28-2.26)	<b>1.79</b> <b>(1.34-2.40)</b>	1.69 (1.37-2.08)	<b>1.85</b> <b>(1.49-2.31)</b>
Foot/Toes	1.22 (0.99-1.52)	<b>1.28</b> <b>(1.02-1.60)</b>	1.12 (0.88-1.42)	1.25 (0.98-1.61)	1.08 (0.84-1.38)	1.24 (0.96-1.60)	1.10 (0.82-1.47)	1.26 (0.93-1.71)	1.23 (0.91-1.67)	<b>1.50</b> <b>(1.10-2.05)</b>	1.17 (0.94-1.45)	<b>1.53</b> <b>(1.22-1.92)</b>

Abbreviations: CI, Confidence Interval; MSK, Musculoskeletal; OR, Odds Ratio; PA, Physical Activity; WHO, World Health Organization

Footnote: A group of participants who did not meet the WHO recommendations of PA (i.e. PA less than 150 min per week) was set as the reference group. The model was adjusted for sex, age, employment status, and depression risk.

**Table 3. Association of PA with the Number of MSK-Pain Locations**

<i>Number of MSK-Pain Locations</i>	<i>Dose of WHO Guideline-Based PA</i>											
	150-300 min		300-450 min		450-600 min		600-750 min		750-900 min		900+ min	
	Crude OR (95% CI)	Adjusted OR (95% CI)	Crude OR (95% CI)	Adjusted OR (95% CI)	Crude OR (95% CI)	Adjusted OR (95% CI)	Crude OR (95% CI)	Adjusted OR (95% CI)	Crude OR (95% CI)	Adjusted OR (95% CI)	Crude OR (95% CI)	Adjusted OR (95% CI)
Minimum 1 location	1.06 (0.95-1.18)	1.10 (0.98-1.23)	1.04 (0.93-1.17)	1.12 (0.99-1.27)	1.01 (0.89-1.14)	1.11 (0.98-1.26)	0.92 (0.80-1.06)	1.04 (0.90-1.20)	1.09 (0.80-1.28)	<b>1.28 (1.10-1.51)</b>	1.05 (0.94-1.17)	<b>1.30 (1.16-1.45)</b>
Minimum 3 locations	0.89 (0.78-1.01)	0.97 (0.85-1.11)	0.80 (0.70-0.93)	0.90 (0.78-1.04)	0.80 (0.69-0.93)	0.93 (0.80-1.08)	0.86 (0.72-1.02)	1.00 (0.84-1.19)	0.93 (0.77-1.12)	1.12 (0.93-1.36)	0.88 (0.77-0.99)	1.08 (0.94-1.23)
Minimum 5 locations	0.76 (0.62-0.93)	0.84 (0.69-1.03)	0.65 (0.51-0.82)	<b>0.75 (0.60-0.95)</b>	0.61 (0.48-0.78)	<b>0.73 (0.57-0.93)</b>	0.74 (0.56-0.97)	0.85 (0.64-1.13)	0.87 (0.66-1.16)	1.09 (0.82-1.45)	0.83 (0.68-1.01)	1.06 (0.87-1.29)
Minimum 10 locations	0.70 (0.45-1.07)	0.76 (0.49-1.17)	0.32 (0.17-0.61)	<b>0.36 (0.19-0.68)</b>	0.57 (0.34-0.98)	0.64 (0.37-1.10)	0.64 (0.35-1.19)	0.67 (0.35-1.40)	0.62 (0.31-1.23)	0.70 (0.35-1.40)	0.61 (0.39-0.95)	0.67 (0.42-1.06)

Abbreviations: CI, Confidence Interval; MSK, Musculoskeletal; OR, Odds Ratio; PA, Physical Activity; WHO, World Health Organization

Footnote: A group of participants who did not meet the WHO recommendations of PA (i.e. PA less than 150 min per week) was set as the reference group. The model was adjusted for sex, age, employment status, and depression risk.





ASAP → base

14.03.2022, 12:20

Page 01

Start

SC02

## Welcome

The outbreak of the novel coronavirus has changed our life within shortest time. In many countries, public life has been reduced or canceled (e.g. by means of business closures, bans of public gathering or quarantine) in order to reduce social contact and, with this, contain the pandemic. For many individuals, regular access to gyms, sports clubs or sports facilities is no longer possible.

We, an international group of scientists from several universities, aim to help all those being affected by the current situation. To promptly create new exercise programs, contents and methods, we conduct a brief survey assessing your physical activity levels well-being during the pandemic. Our survey will take less than 10 minutes.

SC01

The guidelines of good ethical research stipulate that participants in empirical studies explicitly and comprehensively agree to participate.

**Voluntary.** Your participation in this investigation is voluntary. You are free to cancel your participation at any time in this study without incurring any disadvantages.

**Anonymity.** Your data is treated confidentially, will be stored encrypted and password-protected, only be evaluated anonymously and not be passed on to third parties. All collected data will only be used for scientific purposes. Demographic information such as age or gender does not allow a clear conclusion to be drawn with regard to yourself.

**Questions.** If you still have questions about this study, you can find the contact details of the principal investigator of this study in the bottom of each page ('Imprint ASAP').

By participating in this survey (indicated by clicking the 'Participate'-button), I confirm that I am older than 18 years and have read and understood the informed consent.

Participate



1  
2  
3  
4  
5 **Please indicate your sex.**

SD01

- 6  
7  Male  
8  Female  
9  
10  Non-binary  
11  I prefer not to say  
12


13  
14  
15 **What is your age?**

SD02

16  
17  years  
18  
19

20  
21  
22 **Where do you live?**

SD04

23  
24    
25  
26

27  
28 **Where do you work since the virus outbreak in your country?**

SD03

- 29  
30  Remotely (Home office)  
31  Office/regular place of work  
32  both  
33  I do not have a formal employment.  
34  I do not want to tell.  
35  
36  
37  
38  
39  
40

41  
42  
43  
44  
45 **Do you currently work part-time or full-time?**

SD05

- 46  
47  full-time  
48  part-time  
49  I do not want to tell  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

---

**Page 04**

KH

1  
2  
3  
4  
5 **Have you had any symptoms beyond a minor respiratory tract infection since the virus outbreak in your**  
6 **country?**

KH01

7 **Only choose yes, if you had to stay in bed or reduce your regular movement behaviour due to these symptoms.**

8  
9  yes

10  no

---

**Page 05**

Corona

11  
12  
13  
14  
15  
16  
17  
18  
19 **Have you been diagnosed with the novel Coronavirus?**

KH02

20  
21 Only choose "yes" if you have been diagnosed by a helathcare professional.

22  
23  yes

24  no

25  I do not want to tell

---

**Page 06**

Einschraenkung

26  
27  
28  
29  
30  
31  
32  
33  
34  
35 **Please indicate the approximate number of days you have been limited in your ability to leave your home and**  
36 **move freely due to restrictions of public life (e.g. prohibition of face-to-face contact, business closures,**  
37 **lockdowns).**

KH03

38  
39  days

---

**Page 07**

Erklaerung

40  
41  
42  
43  
44  
45  
46  
47  
48  
49 From here, we will repeatedly ask how certain situations and conditions have changed in your country since the outbreak  
50 of the novel coronavirus. For instance, if you just stated to be restricted in your ability to move freely since 14 days,  
51 please always compare the situation during these last 14 days to 14 typical days prior to the outbreak. If you chose 30  
52 days, please compare these 30 days with 30 typical days prior to the outbreak.

KH04

KA09

**Physical activities in leisure time**

We would like to know, how physically active you have been in your **free time** (including commuting from and to work). We only ask about moderate and vigorous activities – light activities do not need to be reported.

Moderate activities are those where your heartbeat increases and you breathe faster (e.g. brisk walking, cycling as a means of transport or as a exercise, heavy gardening, running or recreational sports).

Vigorous activities are those that get your heart racing, make you sweat and so short of breath that you find it difficult to speak (e.g. swimming, running, cycling at high speeds, cardio training, weigh-lifting or team sports such as football).

KA01

**Moderate and vigorous activities**

On a typical week, how much time do you spend in total on both moderate and vigorous physical activities?

Please sum all activities with a minimal duration of 10 minutes. Enter 0, if there was not at least one activity of more than 10 minutes.

before the outbreak  Minutes per week.

since the outbreak  Minutes per week.

KA03

**Vigorous activities only**

How much of that time you indicated above, do you spend in total on **vigorous physical activities** only?

Please sum all activities with a minimal duration of 10 minutes. Enter 0, if there was not at least one activity of more than 10 minutes.

before the outbreak  Minutes per week.

since the outbreak  Minutes per week.

KA10

**Physical activity in your job**

While the previous questions addressed free time, the following two focus on work/occupational time. Again, we only ask about moderate and vigorous activities – light activities do not need to be reported.

Moderate activities are those where your heartbeat increases and you breathe faster (e.g. brisk walking).

Vigorous activities are those that get your heart racing, make you sweat and so short of breath that you find it difficult to speak (e.g. repeated lifting of heavy weights).

**Moderate and vigorous activities**

KA07

Rahmen

On a typical week, how much time do you spend in total on both moderate and vigorous physical activities?

Please sum all activities with a minimal duration of 10 minutes. Enter 0, if there was not at least one activity of more than 10 minutes.

before the outbreak  Minutes per week.

since the outbreak  Minutes per week.

**Vigorous activities only**

KA08

How much of that time you indicated above, do you spend in total on **vigorous physical activities** only?

Please sum all activities with a minimal duration of 10 minutes. Enter 0, if there was not at least one activity of more than 10 minutes.

before the outbreak  Minutes per week.

since the outbreak  Minutes per week.

KA11

Please indicate the impact of the restrictions in public life on your overall level of activity (now including also light and very light activities such as shopping, walking, etc.)

strongly negative  
influenceslight negative  
influence

no influence

modest positive  
impactstrongly positive  
influence

KA05

How did you engage in sport or exercise before the virus outbreak in your country?

Multiple choice possible.

- Gym
- Sports club
- Self-organised outdoor (e.g. running, cycling in nature)
- Self-organised at home (e.g. cycle ergometer, dumbbells)
- others
- not at all

KA06

How did you engage in sport or exercise since the virus outbreak in your country?

Multiple choice possible.

- self-organised outdoor (e.g. running, cycling in nature)
- self-organised at home (e.g. cycle ergometer, dumbbells)
- others
- not at all

WB13

Please indicate whether you suffered from musculoskeletal pain before and/or since the virus outbreak.

The musculoskeletal system comprises all parts of the skeletal system with bones, muscles, ligaments, tendons, joints and their functions.

	no pain	very light pain	light pain	moderate pain	strong pain	very strong pain
before outbreak	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
since outbreak	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

WB14

How much did pain interfere with your normal work (including both work outside the home and housework)?

	no pain	not at all	a little bit	moderately	quite a bit	extremely
before outbreak	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
since outbreak	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

question('WB15', 'combine=WB16')

Please list all body regions where you had pain before (left boxes) and/or side (right boxes) the onset

WB15

WB16

	before outbreak	since outbreak
<b>Multiple selections in both columns are possible.</b>		
I did not have pain.	<input type="checkbox"/>	<input type="checkbox"/>
Neck/cervical spine	<input type="checkbox"/>	<input type="checkbox"/>
Shoulder	<input type="checkbox"/>	<input type="checkbox"/>
Upper arm	<input type="checkbox"/>	<input type="checkbox"/>
Elbow	<input type="checkbox"/>	<input type="checkbox"/>
Forearm	<input type="checkbox"/>	<input type="checkbox"/>
Wrist	<input type="checkbox"/>	<input type="checkbox"/>
Hand	<input type="checkbox"/>	<input type="checkbox"/>
Fingers	<input type="checkbox"/>	<input type="checkbox"/>
Thoracic spine/upper back	<input type="checkbox"/>	<input type="checkbox"/>
Sternum/Ribs	<input type="checkbox"/>	<input type="checkbox"/>
Lumbar spine/lower back	<input type="checkbox"/>	<input type="checkbox"/>
Abdomen	<input type="checkbox"/>	<input type="checkbox"/>
Pelvis/buttock	<input type="checkbox"/>	<input type="checkbox"/>
Hip	<input type="checkbox"/>	<input type="checkbox"/>
Groin	<input type="checkbox"/>	<input type="checkbox"/>
Thigh	<input type="checkbox"/>	<input type="checkbox"/>
Knee	<input type="checkbox"/>	<input type="checkbox"/>
Lower leg	<input type="checkbox"/>	<input type="checkbox"/>
Ankle/achilles tendon	<input type="checkbox"/>	<input type="checkbox"/>
Foot/toes	<input type="checkbox"/>	<input type="checkbox"/>

Please indicate for each of the five statements which is closest to how you have been feeling before the **WB10** outbreak of the novel coronavirus.

	all the time	most of the time	a little more than half of the time	a little less than half of the time	every now and then	at no time
<b>Before the outbreak...</b>						
...I have felt cheerful and in good spirits	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
...I have felt calm and relaxed	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
...I have felt active and vigorous	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
...I woke up feeling fresh and rested	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
...my daily life has been filled with things that interest me	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

Please indicate for each of the five statements which is closest to how you have been feeling since the **WB11** outbreak of the novel coronavirus.

	all the time	most of the time	a little more than half of the time	a little less than half of the time	every now and then	at no time
<b>Since the outbreak</b>						
...I have felt cheerful in good spirits	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
...I have felt calm and relaxed	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
...I have felt active and vigorous	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
...I woke up feeling fresh and rested	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
...my daily life has been filled with things that interest me	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>



In general, how would you rate the influence of restrictions by government due to the novel coronavirus (e.g., the closure of sports facilities and gyms, bans of public gathering or quarantine) on your personal well-being?

WB19

psychological well-being



WB20

physical well-being



Since the outbreak of the novel coronavirus, sport and/or physical activity helps me deal with the overall situation.

WB12



Would you be interested in a free online exercise training program that you could use home-based despite the restrictions in public life?

TP01

- yes
- no

1  
2  
3  
4  
5 **How much time per week would you like to spend for such a training program?**

TP02

6  
7  Minutes per training session/workout

8  
9  
10  
11 **How often would you like to exercise?**

TP04

- 12  
13  daily
- 14  4-6 times a week
- 15  3-4 times a week
- 16  1-2 times a week

17  
18  
19  
20  
21 **Which type of exercise would you like to perform?**

TP03

22  
23 **Multiple choice possible.**

- 24  Strength
- 25  Endurance
- 26  Coordination/Balance
- 27  Cognition
- 28  Flexibility/Stretching
- 29  Relaxation
- 30  no preference

31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43 **Thank you for participating!**

EN04

44  
45 You are welcome to visit us on our homepage as well as on Facebook and Instagram:

EN05



46  
47  
48  
49  
50  
51 [Homepage](#) [Facebook](#) [Instagram](#)

52  
53  
54 **Please feel free to share this survey with your family, work colleagues and friends! Thank you!**

1  
2  
3  
4 **Thank you for participating!**  
5

6  
7  
8 Your answers have been saved, you can now close the browser window.  
9

10  
11  
12  
13 [Imprint ASAP](#) – 2020  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**STROBE 2007 (v4) Statement—Checklist of items that should be included in reports of *cross-sectional studies***

Section/Topic	Item #	Recommendation	Reported on page #
<b>Title and abstract</b>	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1-3
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	1-3
<b>Introduction</b>			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	3-4
Objectives	3	State specific objectives, including any prespecified hypotheses	3-4
<b>Methods</b>			
Study design	4	Present key elements of study design early in the paper	4
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	4-5
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants	5
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	5-6
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	5-6
Bias	9	Describe any efforts to address potential sources of bias	5-6
Study size	10	Explain how the study size was arrived at	5-6
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	5-6
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	5-6
		(b) Describe any methods used to examine subgroups and interactions	5-6
		(c) Explain how missing data were addressed	5-6
		(d) If applicable, describe analytical methods taking account of sampling strategy	N/A
		(e) Describe any sensitivity analyses	N/A
<b>Results</b>			

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	6
		(b) Give reasons for non-participation at each stage	N/A
		(c) Consider use of a flow diagram	N/A
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	6
		(b) Indicate number of participants with missing data for each variable of interest	N/A
Outcome data	15*	Report numbers of outcome events or summary measures	7
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	7-8
		(b) Report category boundaries when continuous variables were categorized	7-8
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	N/A
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	N/A
<b>Discussion</b>			
Key results	18	Summarise key results with reference to study objectives	8-12
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	12
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	11-12
Generalisability	21	Discuss the generalisability (external validity) of the study results	11-12
<b>Other information</b>			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	13

\*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at [www.strobe-statement.org](http://www.strobe-statement.org).

# BMJ Open

## Association between physical activity and musculoskeletal pain: an analysis of international data from the ASAP survey

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-059525.R2
Article Type:	Original research
Date Submitted by the Author:	15-Aug-2022
Complete List of Authors:	Rhim, Hye Chang; Harvard Medical School, Department of Physical Medicine and Rehabilitation; Spaulding Rehabilitation Hospital Tenforde, Adam; Harvard Medical School, Department of Physical Medicine and Rehabilitation; Spaulding Rehabilitation Hospital Mohr, Lisa; Goethe University Frankfurt, Department of Sports Medicine Hollander, Karsten; MSH Medical School Hamburg, Institute of Interdisciplinary Exercise Science and Sports Medicine Vogt, Lutz; Goethe-Universitat Frankfurt am Main, Department of Sports Medicine Groneberg, David; Goethe University Frankfurt, Institute of Occupational Medicine, Social Medicine and Environmental Medicine Wilke, Jan; Goethe-Universitat Frankfurt am Main, Institut of Occupational Medicine, Social Medicine and Environmental Medicine; University of Klagenfurt, Department of Movement Sciences
<b>Primary Subject Heading</b>:	Sports and exercise medicine
Secondary Subject Heading:	Epidemiology, Public health, Sports and exercise medicine, Rehabilitation medicine, Rheumatology
Keywords:	SPORTS MEDICINE, REHABILITATION MEDICINE, Musculoskeletal disorders < ORTHOPAEDIC & TRAUMA SURGERY, PAIN MANAGEMENT

SCHOLARONE™  
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1  
2  
3 **Association between physical activity and musculoskeletal pain: an**  
4  
5  
6 **analysis of international data from the ASAP survey**  
7

8  
9 Hye Chang Rhim\*, Adam Tenforde\*, Lisa Mohr, Karsten Hollander, Lutz Vogt, David A.  
10  
11 Groneberg, Jan Wilke†

12  
13 \* The first two authors equally contributed to this work  
14  
15

16  
17  
18 Hye Chang Rhim, Department of Physical Medicine and Rehabilitation, Harvard Medical  
19 School/Spaulding Rehabilitation Hospital, Boston, MA, USA

20  
21 Adam Tenforde, Department of Physical Medicine and Rehabilitation, Harvard Medical  
22 School/Spaulding Rehabilitation Hospital, Boston, MA, USA

23  
24 Lisa Mohr, Department of Sports Medicine, Goethe University Frankfurt, Frankfurt, Germany

25  
26 Karsten Hollander, Institute of Interdisciplinary Exercise Science and Sports Medicine, Medical  
27 School Hamburg, Hamburg, Germany

28  
29 Lutz Vogt, Department of Sports Medicine, Goethe University Frankfurt, Frankfurt, Germany

30  
31 David A. Groneberg, Institute of Occupational, Social, and Environmental Medicine, Goethe  
32 University, Frankfurt, Germany

33  
34 Jan Wilke, Institute of Occupational, Social, and Environmental Medicine, Goethe University,  
35 Frankfurt, Germany / Department of Movement Sciences, University of Klagenfurt, Austria

36  
37  
38  
39 † Corresponding author: Jan Wilke, Institute of Occupational, Social, and Environmental  
40 Medicine, Goethe University, , Frankfurt, Germany, Email: [jan.wilke@aau.at](mailto:jan.wilke@aau.at)  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



## ABSTRACT

**Objective:** To explore the association of physical activity (PA) with musculoskeletal pain (MSK-pain).

**Design:** Cross-sectional study

**Setting:** 14 countries (Argentina, Australia, Austria, Brazil, Chile, France, Germany, Italy, the Netherlands, Singapore, South Africa, Spain, Switzerland, and the United States of America)

**Participants:** Individuals aged 18 or older

**Primary and secondary outcome measures:** PA volumes were assessed with an adapted version of the Nordic Physical Activity Questionnaire-short (NPAQ-short). Prevalence of MSK-pain was captured by means of a 20-item checklist of body locations. Based on the WHO recommendation on PA, participants were classified as non-compliers (0-150 min/week), compliers (150-300 min/week), double compliers (300-450 min/week), triple compliers (450-600 min/week), quadruple compliers (600-750 min/week), quintuple compliers (750-900 min/week), and top compliers (more than 900 min/week). Multivariate logistic regression was used to obtain adjusted odds ratios of the association between PA and MSK-pain for each body location, correcting for age, sex, employment status, and depression risk.

**Results:** A total of 13,741 participants completed the survey. Compared to non-compliers, compliers had smaller odds of MSK-pain in one location (thoracic pain, OR 0.77, CI 0.64-0.93). Double compliance was associated with reduced pain occurrence in six locations (elbow, OR 0.70, CI 0.50-0.98; forearm, OR 0.63, CI 0.40-0.99; wrist, OR 0.74, CI 0.57-0.98; hand, OR 0.57, CI 0.40-0.79; fingers, OR 0.72, 0.52-0.99; abdomen, OR 0.61, 0.41-0.91). Triple to top compliance was also linked with lower odds of MSK-pain (five locations in triple compliance, three in quadruple compliance, two in quintuple compliance, three in top compliance), but, at the same time, presented increased odds of MSK-pain in some of the other locations.

**Conclusion:** A dose of 300-450 min WHO-equivalent PA/week was associated with lower odds of MSK-pain in six body locations. On the other hand, excessive doses of PA were associated with higher odds of pain in certain body locations.

### Strengths and Limitations of this study

- This is the first large-scale analysis of associations between MSK pain and PA considering multiple anatomical locations
- Large sample size enabled to investigate the associations between different degrees of compliance to physical activity recommended by WHO and MSK-pain
- Administration of the survey in 14 countries allowed participation of diverse populations
- Self-reported data may be subject to recall bias
- Cross-sectional observational design prohibits causal inference

For peer review only

## INTRODUCTION

Musculoskeletal pain (MSK-pain) is a common condition that can have negative physical, psychological, and social impacts.[1] A summary of previous epidemiological studies conducted with diverse techniques and populations revealed that MSK-pain affects between 13.5% and 47% of the general population, with prevalence higher in women and increasing strongly with age.[2] Musculoskeletal conditions contribute to disability, especially in older age groups.[2] It has been reported that disability-adjusted life-years (DALYs), which reflects the years of life lost due to premature mortality and years of life lived with disability, increased by 62% between 1990 and 2016 around the world with 20% surge during the ten-year interval from 2006 to 2016.[3] Most of the increased burden has derived from disability due to increased aging population affected by MSK conditions, and the burden of MSK disorders is expected to increase even more in the future.[4]

Achieving sufficient physical activity (PA) is associated with a variety of positive health outcomes such as substantial risk reduction in all-cause mortality[5] as well as multiple chronic diseases including type 2 diabetes and metabolic syndrome,[6] cancer,[6] and cardiovascular disease.[7] In the light of these positive impacts, World Health Organization (WHO) recommends 150-300 min of moderate-intensity PA, or 75-150 min of vigorous-intensity PA, or aerobic PA with some combination of moderate and vigorous intensities.[8] PA is also considered one of the most important strategies to prevent and manage MSK-pain.[9] However, compared to the available evidence on the association of PA with non-communicable disease, there seems to be a fewer number of studies on the topic of PA and MSK-pain. Furthermore, it is still less clear whether the amounts recommended by WHO are sufficient to elicit benefits in terms of addressing MSK-pain. The few available studies examining the relation of regular PA

1  
2  
3 and MSK-pain tended to focus on influence of PA for specific body locations or specific  
4  
5 diagnoses such as low back pain, neck pain, or osteoarthritis and found inconsistent results.[10]  
6  
7 Other studies have evaluated the associations between PA and pain in occupational settings such  
8  
9 as among physical therapists or teaching staff.[11,12] Particularly, the interplay between the  
10  
11 volume of PA and MSK-pain within the general population has been less explored.  
12  
13

14  
15 The purpose of this study was to explore the association of total PA with presence of  
16  
17 MSK-pain in a variety of anatomical locations including both upper and lower extremities. We  
18  
19 hypothesized that greater time spent in PA than WHO recommendation would be associated with  
20  
21 the absence of MSK-pain in more body regions, but that excess time performing PA might be  
22  
23 associated with the presence of MSK-pain in more body regions.  
24  
25  
26  
27

## 28 **METHODS**

### 29 *Study Design*

30  
31  
32 This article presents an explorative analysis of pre-pandemic baseline data on PA and  
33  
34 MSK-pain assessed during the ASAP (Activity and Health during the SARS-CoV-2 Pandemic)  
35  
36 survey. The survey was administered with results collected between April 3 and May 9, 2020,  
37  
38 including participants from 14 countries (Argentina, Australia, Austria, Brazil, Chile, France,  
39  
40 Germany, Italy, the Netherlands, Singapore, South Africa, Spain, Switzerland, and the United  
41  
42 States of America (USA)).[13-16] Ethical approval was obtained from the ethics committees of  
43  
44 the study center and collaborating institutions. All participants provided digital informed  
45  
46 consent.  
47  
48  
49  
50  
51  
52

### 53 *Participants*

1  
2  
3 Eligibility for participation in the ASAP survey was limited to individuals aged 18 or  
4 older living in participating countries. Recruitment was performed online using promotion by  
5 health-related organizations, mailing lists, and social media advertising (e.g. Facebook,  
6 Instagram, Twitter).  
7  
8  
9  
10  
11  
12  
13

### 14 *Questionnaire*

15  
16 To capture PA, the ASAP survey incorporated an adapted version of the Nordic Physical  
17 Activity Questionnaire-short (NPAQ-short). The instrument retrospectively assessed the  
18 amounts of moderate and combined moderate and vigorous activities (min/week) during leisure  
19 and occupational time. Moderate activities were defined as those that increase heart rate or  
20 breathing, and vigorous activities were defined as those that make heart racing, sweating, and  
21 shortness of breath. The questionnaire asked how much time participants spent in total on both  
22 moderate and vigorous PA on a typical week, and the time spent in all activities with a minimal  
23 duration of 10 minutes was asked to be added and entered in the form. The NPAQ-short has been  
24 shown to be reliable (test-retest reliability:  $\rho = 0.80$  to  $0.82$ ) and valid for observing  
25 compliance with the WHO recommendations on PA.[17] The questionnaire was available in 7  
26 different languages (Dutch, English, German, French, Italian, Brazilian-Portuguese, Spanish),  
27 and clarity and comprehensibility were validated by native speakers through forward and  
28 backward translation.  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45

46 Prevalence of MSK-pain was captured by means of binary responses (yes/no) to an  
47 adapted 20-item checklist from a consensus statement on epidemiological injury reporting.[18]  
48  
49 Body locations were categorized as follows: neck/cervical spine, shoulder, upper arm, elbow,  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 forearm, wrist, hand, fingers, thoracic spine, ribs, lower back, abdomen, pelvis/gluteal, hip,  
4  
5 groin, thigh, knee, lower leg, ankle/Achilles tendon, foot/toe.  
6  
7

8 The English version of the ASAP survey can be found in Supplemental File 1.  
9

### 10 11 12 *Data Processing and Statistical Analysis* 13

14 Self-reported PA was categorized as multiples of compliance with WHO guidelines  
15 which recommend 150-300 minutes/week of moderate activity, 75-150 minutes/week of  
16 vigorous activity, or any adequate combination of both.[8] We used the formula (minutes of  
17 moderate-to-vigorous PA – minutes of vigorous PA) + minutes of vigorous PA \*2 to classify  
18 participants as non-compliers (0-150 min/week), compliers (150-300 min/week), double  
19 compliers (300-450 min/week), triple compliers (450-600 min/week), quadruple compliers (600-  
20 750 min/week), quintuple compliers (750-900 min/week), and top compliers (more than 900  
21 min/week). In addition to the assessment of PA, participants were asked where they worked in  
22 multiple choices which also included a ‘no employment’ option, and the answers to this question  
23 were used to categorize participants into being employed or not employed for our analysis. Also,  
24 the WHO-Well-Being Index (WHO-5) was used to capture depression risk as validated by  
25 previous research.[19]  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41

42 For each body region, univariate binary logistic regression was conducted to calculate the  
43 unadjusted odds ratio (OR) of the association between pain (dependent variable: yes/no) and PA.  
44 In a similar way, univariate binary logistic regression was then used to identify associations of  
45 pain (dependent variable) and potential confounding variables (sex, age, employment status,  
46 depression risk). Finally, multivariate binary logistic regression was performed including these  
47 confounding variables (if relevant) to obtain the adjusted ORs and 95% confidence interval (CI)  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 of the association between the volume of PA and pain (dependent variable). As participants may  
4 have a strongly varying number of pain locations and as the impact of pain on the individual may  
5 vary with the number of affected body regions, additional analyses, using the same procedures as  
6 described above (binary logistic regression corrected for confounders), were performed to obtain  
7 adjusted OR for pain in only one, at least 3, 5, or 10 body locations.  
8  
9

10 All data analyses were conducted using SPSS 22 (SPSS INC., Armonk, NY, USA), and the  
11 significance level was set to  $\alpha = 0.05$ .  
12  
13

### 14 *Patient and Public Involvement*

15 Members of the target population without medical background were involved in the  
16 designing phase of the ASAP questionnaire. The questionnaire was face validated for each  
17 language with five non-academic individuals. Feedback on comprehension and clarity of the  
18 wording was used.  
19  
20  
21  
22

## 23 **RESULTS**

24 Valid datasets were identified for 13,741 participants ( $38 \pm 15$  years, minimum 18 and  
25 maximum 100, 59% females). The demographic data are summarized in the Table 1. 2604  
26 individuals did not meet the WHO recommendation of PA while n=2735 belonged to 150-300  
27 min group, n=1957 to 300-450 min group, n=1749 to 450-600 min group, n=1066 to 600-750  
28 min group, n=849 to 750-900 min group, and n=2781 to 900+ min group. Comprehensive  
29 results are summarized in the Table 2 and 3.  
30  
31  
32  
33  
34

35 Compared to inactive individuals, simple guideline compliance was associated with  
36 lower odds of suffering from MSK-pain in one body location (thoracic pain, OR 0.77, CI 0.64-  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57

0.93 Table 1). Double compliance was associated with lower odds of suffering from MSK-pain in six locations (elbow, OR 0.70, CI 0.50-0.98; forearm, OR 0.63, CI 0.40-0.99; wrist, OR 0.74, CI 0.7-0.98; hand, OR 0.57, CI 0.40-0.79; fingers, OR 0.72, CI 0.52-0.99; abdomen, OR 0.61, CI 0.41-0.91). Although higher amounts of PA were associated with lower odds of suffering from MSK-pain in variable numbers of locations (five body locations in triple compliance, three in quadruple compliance, two in quintuple compliance, three in top compliance), they were also associated with higher odds of suffering from MSK-pain in other locations. Specifically, triple compliance was associated with presence of MSK-pain in thigh (OR 1.41, CI 1.03-1.92), knee (OR 1.25, CI 1.06-1.50), and ankle/Achilles tendon (OR 1.47, CI 1.14-1.88). Quadruple compliance increased pain locations to four, quintuple compliance to six, and top compliance to seven.

Triple compliance was associated with lower odds to have a total of 5 or more (OR 0.75, CI 0.60-0.95) or 10 or more (OR 0.36, CI 0.19-0.68) pain locations, and quadruple compliance was associated with lower odds to have 5 or more pain locations (OR 0.73, CI 0.57-0.93). However, quintuple and top compliances were associated with higher odds of having a minimum one pain location (OR 1.28, CI 1.10-1.51 and 1.30, CI 1.16-1.45 respectively).

## DISCUSSION

The purpose of the present study was to explore the relation between PA and MSK-pain. Previous research focused on the impact of PA on specific locations of MSK-pain (e.g., low back and neck[20]) or certain occupational settings.[11,12] Our large-scale multinational study is novel in that it identified the associations between different degrees of compliance to PA recommended by WHO and multiple body locations in the general population after adjusting for multiple



1  
2  
3 cofounding factors including age, which is known to be positively associated with MSK-pain  
4 prevalence.  
5  
6

7  
8 Guideline compliance (150-300 min per week) was weakly associated with MSK pain,  
9 showing lower odds of having pain only in thoracic spine but higher odds in foot/toes. In  
10 contrast, double compliance (300-450 min per week) substantially increased the number of  
11 locations that were associated with lowers odds of MSK-pain to six and thus seems to represent  
12 the optimal dose when PA is undertaken to prevent MSK. Finally, higher levels of PA (triple to  
13 top compliance) were associated with less odds of having pain in multiple upper body locations  
14 but paradoxically contributed to higher odds of having lower extremity pain. Notably,  
15 participating in 300-600 min of PA per week was associated with lower odds of having pain in  
16 upper extremities, neck, and thoracic and lumbar spine. In contrast, participating in greater than  
17 450 min of PA per week was associated with higher odds of having pain in the lower extremity.  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32

### 33 *Time spent in PA and pain in neck, back, and upper extremity*

34  
35 A previous systematic review showed that there was limited evidence for no association  
36 between PA and neck pain.[20] However, our study found that participating in PA between 450-  
37 900+ min was associated with lower odds of having pain in neck/cervical spine. Several  
38 epidemiological studies have demonstrated that certain postures sustained for prolonged duration  
39 combined with sedentary lifestyle were associated with neck pain.[21-23] Therefore, increased PA  
40 levels may be helpful to consider in those at risk for neck pain.  
41  
42  
43  
44  
45  
46  
47  
48

49 Association between PA and thoracic spine has been less explored,[24] but a recent  
50 observational study found that PA less than 150 min per week was associated with reduced  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 thoracic mobility.[25] Our findings build on previous research in that PA less than 150 min per  
4 week is also associated with higher odds of having pain in the thoracic spine.  
5  
6

7  
8 While it is generally accepted that PA and exercise are beneficial in the management of  
9 acute and chronic low back pain, a previous systematic review could not identify either positive  
10 or negative relationship.[26] One study suggested that the relationship between the level of  
11 activity and back pain might be explained by a U-shaped curve that suggests both low and  
12 excessive PA may increase the risk of low back pain.[27] Our findings partly support this  
13 concept as PA of 450-750 min was associated with lower odds of low back pain while lower or  
14 higher PA than that range did not have significant association.  
15  
16  
17  
18  
19  
20  
21  
22

23  
24 PA in the range of 300-600 min was also associated with lower odds of having pain in  
25 several locations in the upper extremity such as elbow, forearm, wrist, hand, and fingers. PA  
26 exceeding 750 min was associated with higher odds of shoulder pain. The underlying  
27 mechanisms of how PA modulates pain are not completely understood, but several pathways  
28 have been proposed. Animal study findings suggest regular PA may act on the central nervous  
29 system (CNS) and alter rate of pain hypersensitivity, dysregulation of pain modulation, and  
30 development of chronic pain.[28-30] In humans, it has been proposed that PA may intervene  
31 excitability and inhibition in the CNS,[31-33] and anti-inflammatory and antioxidant effects of  
32 regular PA might diminish the processes contributing to central sensitization.[34-36] Other  
33 proposed mechanisms in humans include the activation of opioid and serotonin pathways[37] or  
34 involvement of endocannabinoid system[38] induced from regular PA which could exert  
35 analgesic effects. While further research is needed to elucidate how much and what type of PA  
36 can induce such changes to modulate pain, our results suggest that PA between 300-600 mins per  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 week may be sufficient for spinal conditions and upper extremity pain, with PA exceeding 750  
4  
5 min associated with higher likelihood of shoulder pain.  
6  
7  
8  
9

### 10 *Association of PA and lower extremity pain*

11  
12 The association of PA to lower extremity pain was different than what was observed for  
13  
14 upper extremity and spine conditions. Our results suggest PA exceeding 450 min was associated  
15  
16 with higher odds of MSK-pain in lower extremity. These findings may be partially explained by  
17  
18 higher amounts of PA are likely to involve greater use of the lower extremity. In the United  
19  
20 States, it has been reported that walking is the most popular form of exercise followed by biking,  
21  
22 yard work, strength training, dancing, and running, which are activities that commonly place  
23  
24 physical demands through the lower extremity.[39] Running is one of the most popular exercises  
25  
26 in the world and has been shown to result in lower extremity pain in multiple anatomical  
27  
28 locations with nearly all (94.7% of runners) reporting experience of pain at least once after  
29  
30 running.[40]  
31  
32  
33  
34

35 We also observed that greater PA was associated with a higher number of sites of MSK-  
36  
37 pain in the lower extremity. A dose response was observed: 450-600 min was associated with  
38  
39 pain in three anatomical regions, 600-750 min with pain in four anatomical regions, 750-900 min  
40  
41 with five anatomical regions, and 900+ min with six anatomical regions. The optimal PA level to  
42  
43 reduce pain in those with existing musculoskeletal lower extremity pain is unknown. A prior  
44  
45 study reported that a minimum of 45 total moderate-vigorous min per week was sufficient to  
46  
47 elicit improved or sustained high function with lower-extremity symptoms regardless of age,  
48  
49 gender, body mass index, or presence of knee osteoarthritis.[41] Our findings of PA ranging from  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 150-450 min not increasing the odds of having pain in the lower extremities suggest this range  
4  
5 might be appropriate to be safe and promote other health benefits.  
6  
7  
8  
9

### 10 *Clinical implication*

11  
12 While the WHO 2020 guidelines on PA recommend 150-300 min of moderate-intensity  
13  
14 PA, or 75-150 min of vigorous-intensity PA, or some equivalent combination of moderate-  
15  
16 intensity and vigorous-intensity aerobic PA per week for optimal health outcomes,[8] the current  
17  
18 study suggests that more PA beyond the WHO recommendation may be necessary to decrease  
19  
20 the odds of having pain particularly in the upper extremity. Our findings suggest a target of 300-  
21  
22 450 min of PA per week could be optimal for preventing pain in the upper extremity without  
23  
24 clear associated higher rate of lower extremity pain. Also, this range was associated with lower  
25  
26 odds of having pain in multiple number of locations. Recognizing concerns on higher prevalence  
27  
28 of pain in low back, neck, and thoracic spine increased during the COVID-19 pandemic,[15] PA  
29  
30 target of the higher target of 450 min of weekly exercise may be helpful in this population. Our  
31  
32 results suggest exceeding 450 min of PA may not be advisable for those with increased concern  
33  
34 for lower extremity pain. Furthermore, PA above 750 minutes was associated with having at  
35  
36 least one pain location.  
37  
38  
39  
40  
41  
42  
43

### 44 *Limitation*

45  
46 While our findings derived from a large-scale multinational study of participants, we do  
47  
48 note potential limitations. Self-report of PA and MSK-pain are limited by reporting bias and  
49  
50 inaccuracy including risk for over-reporting level of PA.[42,43] The cross-sectional study design  
51  
52 limits our understanding between PA and the etiology of MSK-pain. Also, we are limited in  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 ability in discriminating the types of PA to report of MSK-pain by anatomical locations. We  
4  
5 were not able to distinguish or identify bilateral MSK-pain from our questionnaire as well.  
6  
7 Furthermore, because a separate analysis was run for each body region, there is a risk of multiple  
8  
9 testing problem. Since our analysis was explorative in nature, further prospective cohort or  
10  
11 interventional studies are needed to elucidate the best form and dose of PA to address MSK-pain  
12  
13 by anatomical location and specific musculoskeletal injury, and additionally investigate the role  
14  
15 of MSK-pain intensity instead of using a binary (yes/no) classification.  
16  
17  
18  
19  
20

## 21 CONCLUSION

22  
23  
24 Our findings showed that PA time above the WHO recommendations was associated with  
25  
26 lower odds of having pain in multiple locations such as neck, thoracic spine, low back, and in the  
27  
28 upper extremities. Especially, undertaking PA for 300-450 min per week was associated with  
29  
30 reduced pain occurrence in six locations, elbow, forearm, wrist, hand, fingers, and abdomen.  
31  
32

33 **Acknowledgment:** The authors acknowledge the valuable help from the following authors with  
34 promoting ASAP survey for data collection (in alphabetical order): Benedict Tan, Bernhard  
35 Novak, Celso Ramírez, Chiara Fossati, Christoph Heidt, Daniel E. Lieberman, David Jimenez-  
36 Pavon, Evert Verhagen, Fabio Pigozzi, Falk Richter, Fernando Laíño, Johannes Jaunig, Julian  
37 David Pillay, Luiz Carlos Hespanhol Junior, Marcela González-Gross, Matteo Sattler, Mireille  
38 van Poppel, Pascal Edouard, Steffen Willwacher  
39  
40

41 **Funding:** This research received no external funding.  
42

43 **Data Availability Statement:** Data are available upon reasonable request  
44

## 45 Ethics Statements

46  
47 -Ethics approval: This study was approved by the University of Queensland Health and  
48 Behavioural Sciences (2020000693), Ethical committee of the University of Graz (GZ. 39/62/63  
49 ex 2019/20), Research Ethics Committee of Fundación Instituto Superior de Ciencias de la Salud  
50 (DEPINV CODE: 11/20), Research Ethics Committee of the Universidade Cidade de São Paulo  
51 (CAAE: 30555320.0.0000.0008), Institutional Ethics Committee of the University of Santiago  
52 de Chile (n° 123/2020), Saint-Etienne University Hospital Ethical Committee (IORG0007394;  
53 IRBN492020/CHUSTE), Ethics Committee of the Faculty of Psychology and Sports Sciences of  
54 Goethe University Frankfurt (no. 2020-13), Comitato di Ateneo per la Ricerca, Università degli  
55  
56  
57

1  
2  
3 Studi di Roma “Foro Italico” (CAR 43/2020), Medical Ethical Committee of Amsterdam UMC  
4 (2020.192), Institutional Research Ethics Committee of Durban University of Technology (IREC  
5 042/20), SingHealth Centralised Institutional Review Board (2020/2287), Cantonal Ethics  
6 Committee Northwest Switzerland (2020-01058), Ethics Committee of Universidad Politécnica  
7 de Madrid (20200507-1), and Partners Human Research Committee (2020P000963)  
8  
9

10 -Digital informed consent was obtained from all subjects involved in the study.  
11

12 **Authors Contribution:** HCR/AT: data collection, interpretation, drafting and critical revision of  
13 the manuscript, LM, KH, LV, DG: data collection, critical revision of the manuscript, JW:  
14 conception/design, data collection, interpretation, critical revision of the manuscript  
15

16 Competing interests: None declared.  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## REFERENCES

1. Paananen, M.; Taimela, S.; Auvinen, J.; Tammelin, T.; Zitting, P.; Karppinen, J. Impact of self-reported musculoskeletal pain on health-related quality of life among young adults. *Pain Med* **2011**, *12*, 9-17.
2. Cimmino, M.A.; Ferrone, C.; Cutolo, M. Epidemiology of chronic musculoskeletal pain. *Best Pract Res Clin Rheumatol* **2011**, *25*, 173-183.
3. Collaborators, G.D.a.H. Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet* **2017**, *390*, 1260-1344, doi:10.1016/s0140-6736(17)32130-x.
4. Smith, E.; Hoy, D.G.; Cross, M.; Vos, T.; Naghavi, M.; Buchbinder, R.; Woolf, A.D.; March, L. The global burden of other musculoskeletal disorders: estimates from the Global Burden of Disease 2010 study. *Ann Rheum Dis* **2014**, *73*, 1462-1469, doi:10.1136/annrheumdis-2013-204680.
5. Ekelund, U.; Tarp, J.; Steene-Johannessen, J.; Hansen, B.H.; Jefferis, B.; Fagerland, M.W.; Whincup, P.; Diaz, K.M.; Hooker, S.P.; Chernofsky, A. Dose-response associations between accelerometry measured physical activity and sedentary time and all cause mortality: systematic review and harmonised meta-analysis. *BMJ* **2019**, *366*.
6. Lee, I.-M.; Shiroma, E.J.; Lobelo, F.; Puska, P.; Blair, S.N.; Katzmarzyk, P.T.; Group, L.P.A.S.W. Effect of physical inactivity on major non-communicable diseases worldwide: an analysis of burden of disease and life expectancy. *Lancet* **2012**, *380*, 219-229.
7. Kyu, H.H.; Bachman, V.F.; Alexander, L.T.; Mumford, J.E.; Afshin, A.; Estep, K.; Veerman, J.L.; Delwiche, K.; Iannarone, M.L.; Moyer, M.L. Physical activity and risk of breast cancer, colon cancer, diabetes, ischemic heart disease, and ischemic stroke events: systematic review and dose-response meta-analysis for the Global Burden of Disease Study 2013. *BMJ* **2016**, *354*.
8. Bull, F.C.; Al-Ansari, S.S.; Biddle, S.; Borodulin, K.; Buman, M.P.; Cardon, G.; Carty, C.; Chaput, J.-P.; Chastin, S.; Chou, R. World Health Organization 2020 guidelines on physical activity and sedentary behaviour. *Br J Sports Med* **2020**, *54*, 1451-1462.
9. Lin, I.; Wiles, L.; Waller, R.; Caneiro, J.P.; Nagree, Y.; Straker, L.; Maher, C.G.; O'Sullivan, P.P.B. Patient-centred care: the cornerstone for high-value musculoskeletal pain management. *Br J Sports Med* **2020**, *54*, 1240-1242, doi:10.1136/bjsports-2019-101918.
10. Geneen, L.J.; Moore, R.A.; Clarke, C.; Martin, D.; Colvin, L.A.; Smith, B.H. Physical activity and exercise for chronic pain in adults: an overview of Cochrane Reviews. *Cochrane Database Syst Rev* **2017**.
11. Ezzatvar, Y.; Calatayud, J.; Andersen, L.; Casaña, J. Are moderate and vigorous leisure-time physical activity associated with musculoskeletal pain? a cross-sectional study among 981 physical therapists. *Am J Health Promot* **2020**, *34*, 67-70.
12. Tami, A.M.; Bika Lele, E.C.; Mekoulou Ndongo, J.; Ayina Ayina, C.N.; Guessogo, W.R.; Lobe Tanga, M.-Y.; Owona Manga, L.J.; Temfemo, A.; Bongue, B.; Mandengue, S.H. Epidemiology of Musculoskeletal Disorders among the Teaching Staff of the University of Douala, Cameroon: Association with Physical Activity Practice. *Int J Environ Res Public Health* **2021**, *18*, 6004.
13. Wilke, J.; Mohr, L.; Tenforde, A.S.; Vogel, O.; Hespanhol, L.; Vogt, L.; Verhagen, E.; Hollander, K. Activity and health during the SARS-CoV2 pandemic (ASAP): study protocol for a multi-national network trial. *Front Med* **2020**, *7*, 302.
14. Wilke, J.; Mohr, L.; Tenforde, A.S.; Edouard, P.; Fossati, C.; González-Gross, M.; Ramirez, C.S.; Laiño, F.; Tan, B.; Pillay, J.D. Restrict exercise! Preferences regarding digital home training programs



- during confinements associated with the COVID-19 pandemic. *Int J Environ Res Public Health* **2020**, *17*, 6515.
15. Wilke, J.; Mohr, L.; Tenforde, A.S.; Edouard, P.; Fossati, C.; González-Gross, M.; Sánchez Ramírez, C.; Laiño, F.; Tan, B.; Pillay, J.D. A pandemic within the pandemic? Physical activity levels substantially decreased in countries affected by COVID-19. *Int J Environ Res Public Health* **2021**, *18*, 2235.
  16. Wilke, J.; Hollander, K.; Mohr, L.; Edouard, P.; Fossati, C.; González-Gross, M.; Sánchez Ramírez, C.; Laiño, F.; Tan, B.; Pillay, J.D. Drastic reductions in mental well-being observed globally during the COVID-19 pandemic: results from the ASAP survey. *Front Med* **2021**, *8*, 246.
  17. Danquah, I.H.; Petersen, C.B.; Skov, S.S.; Tolstrup, J.S. Validation of the NPAQ-short—a brief questionnaire to monitor physical activity and compliance with the WHO recommendations. *BMC Public Health* **2018**, *18*, 1-10.
  18. Bahr, R.; Clarsen, B.; Derman, W.; Dvorak, J.; Emery, C.A.; Finch, C.F.; Hägglund, M.; Junge, A.; Kemp, S. International Olympic Committee consensus statement: methods for recording and reporting of epidemiological data on injury and illness in sports 2020 (including the STROBE extension for sports injury and illness surveillance (STROBE-SIIS)). *Orthop J Sports Med* **2020**, *8*, 2325967120902908.
  19. Topp, C.W.; Østergaard, S.D.; Søndergaard, S.; Bech, P. The WHO-5 Well-Being Index: a systematic review of the literature. *Psychother Psychosom* **2015**, *84*, 167-176, doi:10.1159/000376585.
  20. Sitthipornvorakul, E.; Janwantanakul, P.; Purepong, N.; Pensri, P.; van der Beek, A.J. The association between physical activity and neck and low back pain: a systematic review. *Eur Spine J* **2011**, *20*, 677-689.
  21. Ortiz-Hernández, L.; Tamez-González, S.; Martínez-Alcántara, S.; Méndez-Ramírez, I. Computer use increases the risk of musculoskeletal disorders among newspaper office workers. *Arch Med Res* **2003**, *34*, 331-342.
  22. Janwantanakul, P.; Pensri, P.; Jiamjarasrangsi, W.; Sinsongsook, T. Associations between prevalence of self-reported musculoskeletal symptoms of the spine and biopsychosocial factors among office workers. *J Occup Health* **2009**, 0901270054-0901270054.
  23. Cagnie, B.; Danneels, L.; Van Tiggelen, D.; De Loose, V.; Cambier, D. Individual and work related risk factors for neck pain among office workers: a cross sectional study. *Eur Spine J* **2007**, *16*, 679-686.
  24. Briggs, A.M.; Smith, A.J.; Straker, L.M.; Bragge, P. Thoracic spine pain in the general population: prevalence, incidence and associated factors in children, adolescents and adults. A systematic review. *BMC Musculoskelet Disord* **2009**, *10*, 1-12.
  25. Heneghan, N.R.; Baker, G.; Thomas, K.; Falla, D.; Rushton, A. What is the effect of prolonged sitting and physical activity on thoracic spine mobility? An observational study of young adults in a UK university setting. *BMJ Open* **2018**, *8*, e019371.
  26. Hendrick, P.; Milosavljevic, S.; Hale, L.; Hurley, D.; McDonough, S.; Ryan, B.; Baxter, G. The relationship between physical activity and low back pain outcomes: a systematic review of observational studies. *Eur Spine J* **2011**, *20*, 464-474.
  27. Heneweer, H.; Vanhees, L.; Picavet, H.S.J. Physical activity and low back pain: a U-shaped relation? *Pain* **2009**, *143*, 21-25.
  28. Bobinski, F.; Ferreira, T.A.A.; Córdova, M.M.; Dombrowski, P.A.; da Cunha, C.; do Espírito Santo, C.C.; Poli, A.; Pires, R.G.W.; Martins-Silva, C.; Sluka, K.A. Role of brainstem serotonin in analgesia produced by low-intensity exercise on neuropathic pain following sciatic nerve injury in mice. *Pain* **2015**, *156*, 2595.



- 1  
2  
3 29. Sluka, K.A.; O'Donnell, J.M.; Danielson, J.; Rasmussen, L.A. Regular physical activity prevents  
4 development of chronic pain and activation of central neurons. *J Appl Physiol* **2013**, *114*, 725-  
5 733.
- 6 30. Stagg, N.J.; Mata, H.P.; Ibrahim, M.M.; Henriksen, E.J.; Porreca, F.; Vanderah, T.W.; Philip Malan,  
7 T. Regular exercise reverses sensory hypersensitivity in a rat neuropathic pain model: role of  
8 endogenous opioids. *Anesthesiology* **2011**, *114*, 940-948.
- 9 31. Geva, N.; Defrin, R. Enhanced pain modulation among triathletes: a possible explanation for  
10 their exceptional capabilities. *Pain* **2013**, *154*, 2317-2323.
- 11 32. Naugle, K.M.; Ohlman, T.; Naugle, K.E.; Riley, Z.A.; Keith, N.R. Physical activity behavior predicts  
12 endogenous pain modulation in older adults. *Pain* **2017**, *158*, 383-390.
- 13 33. Naugle, K.M.; Riley, J.L. Self-reported physical activity predicts pain inhibitory and facilitatory  
14 function. *Med Sci Sports Exerc* **2014**, *46*, 622.
- 15 34. Radak, Z.; Chung, H.Y.; Koltai, E.; Taylor, A.W.; Goto, S. Exercise, oxidative stress and hormesis.  
16 *Ageing Res Rev* **2008**, *7*, 34-42.
- 17 35. Woods, J.A.; Wilund, K.R.; Martin, S.A.; Kistler, B.M. Exercise, inflammation and aging. *Aging Dis*  
18 **2012**, *3*, 130.
- 19 36. Dhondt, E.; Danneels, L.; Van Oosterwijck, S.; Palmans, T.; Rijckaert, J.; Van Oosterwijck, J. The  
20 influence of physical activity on the nociceptive flexion reflex in healthy people. *Eur J Pain* **2021**,  
21 *25*, 774-789.
- 22 37. Tour, J.; Löfgren, M.; Mannerkorpi, K.; Gerdle, B.; Larsson, A.; Palstam, A.; Bileviciute-Ljungar, I.;  
23 Bjersing, J.; Martin, I.; Ernberg, M., et al. Gene-to-gene interactions regulate endogenous pain  
24 modulation in fibromyalgia patients and healthy controls-antagonistic effects between opioid  
25 and serotonin-related genes. *Pain* **2017**, *158*, 1194-1203,  
26 doi:10.1097/j.pain.0000000000000896.
- 27 38. Tantimonaco, M.; Ceci, R.; Sabatini, S.; Catani, M.V.; Rossi, A.; Gasperi, V.; Maccarrone, M.  
28 Physical activity and the endocannabinoid system: an overview. *Cell Mol Life Sci* **2014**, *71*, 2681-  
29 2698.
- 30 39. Ham, S.A.; Kruger, J.; Tudor-Locke, C. Participation by US adults in sports, exercise, and  
31 recreational physical activities. *J Phys Act Health* **2009**, *6*, 6-14.
- 32 40. Rhim, H.C.; Kim, S.J.; Jeon, J.S.; Nam, H.W.; Jang, K.M. Prevalence and risk factors of running-  
33 related injuries in Korean non-elite runners: a cross-sectional survey study. *J Sports Med Phys*  
34 *Fitness* **2021**, *61*, 413-419, doi:10.23736/s0022-4707.20.11223-4.
- 35 41. Dunlop, D.D.; Song, J.; Lee, J.; Gilbert, A.L.; Semanik, P.A.; Ehrlich-Jones, L.; Pellegrini, C.A.; Pinto,  
36 D.; Ainsworth, B.; Chang, R.W. Physical activity minimum threshold predicting improved function  
37 in adults with Lower-Extremity symptoms. *Arthritis Care Res* **2017**, *69*, 475-483.
- 38 42. Valanou, E.; Bamia, C.; Trichopoulou, A. Methodology of physical-activity and energy-  
39 expenditure assessment: a review. *J Public Health* **2006**, *14*, 58-65.
- 40 43. Schmier, J.; Halpern, M. Patient recall and recall bias of health state and health status. *Expert*  
41 *Rev Pharmacoecon Outcomes Res.* 2004; *4* (2): 159-63.
- 42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Table 1. Demographic data of the participants by countries**

Country	ARG	AUS	AUT	BRA	CHE	CHL	DEU	ESP	FRA	ITA	NLD	SGP	USA	ZAF	Others	Total
<b>Sex (M/F)</b>	429/494	56/248	192/546	620/948	115/212	471/766	696/1356	310/277	1200/1046	348/453	50/129	437/434	364/711	236/293	108/122	5632/8035
<b>Age (SD)</b>	37.1 (15.4)	41.6 (14.1)	27.3 (9.6)	34.2 (10.6)	37.3 (11.5)	31.5 (13.6)	40.4 (16.3)	43.0 (13.4)	43.3 (16.9)	38.5 (15.3)	47.5 (14.0)	40.1 (12.1)	43.1 (14.0)	32.4 (14.3)	40.0 (13.5)	38.3 (15.1)
<b>WHO-5 (SD)</b>	54.3 (17.8)	50.1 (14.8)	55.0 (16.5)	53.0 (16.0)	50.4 (15.2)	54.7 (18.2)	52.9 (17.0)	49.2 (15.8)	48.3 (14.8)	56.3 (17.3)	49.0 (14.7)	52.2 (17.6)	49.4 (14.9)	52.2 (21.1)	51.2 (17.2)	52.0 (16.8)
<b>Employment (Yes, %)</b>	61.9	86.8	62.7	78.8	96.0	59.2	73.2	79.8	69.9	65.9%	77.1	88.8	84.1	53.7	85.0	72.8
<b>MVPA (SD)</b>	488.7 (596.2)	352.3 (340.0)	384.6 (408.7)	396.4 (454.9)	379.0 (458.1)	385.7 (518.3)	438.6 (481.3)	493.2 (617.0)	527.9 (516.0)	566.2 (635.3)	506.5 (420.5)	376.5 (445.7)	401.0 (348.0)	310.6 (455.8)	437.8 (529.7)	439.5 (498.7)
<b>VPA (SD)</b>	218.7 (338.0)	121.3 (152.4)	141.4 (206.5)	202.0 (305.7)	130.6 (152.6)	153.9 (287.9)	146.9 (226.5)	188.4 (295.2)	234.7 (343.3)	247.2 (350.1)	200.2 (225.7)	171.0 (302.4)	195.9 (230.0)	144.1 (272.7)	203 (275.6)	186.4 (288.8)

Abbreviations: F, Female; M, Male; MVPA, Moderate to Vigorous Physical Activity; SD, Standard Deviation; VPA, Vigorous Physical Activity, WHO-5, The 5-item World Health Organization Well-Being Index

Country Abbreviations: ARG, Argentina; AUS, Australia; AUT, Austria; BRA, Brazil; CHE, Switzerland; CHL, Chile; DEU, Germany; ESP, Spain; FRA, France; ITA, Italy; NLD, Netherlands; SGP, Singapore; USA, United States of America; ZAF, South Africa

Table 2. Association of PA with MSK-Pain by Anatomical Locations

Location of MSK-Pain	Dose of WHO Guideline-Based PA											
	150-300 min		300-450 min		450-600 min		600-750 min		750-900 min		900+ min	
	Crude OR (95% CI)	Adjusted OR (95% CI)	Crude OR (95% CI)	Adjusted OR (95% CI)	Crude OR (95% CI)	Adjusted OR (95% CI)	Crude OR (95% CI)	Adjusted OR (95% CI)	Crude OR (95% CI)	Adjusted OR (95% CI)	Crude OR (95% CI)	Adjusted OR (95% CI)
Neck/Cervical	0.89 (0.79-1.01)	0.99 (0.87-1.12)	0.76 (0.67-0.88)	0.89 (0.77-1.03)	0.66 (0.57-0.76)	<b>0.78</b> <b>(0.67-0.91)</b>	0.62 (0.52-0.74)	<b>0.75</b> <b>(0.62-0.90)</b>	0.63 (0.52-0.77)	<b>0.82</b> <b>(0.67-1.00)</b>	0.59 (0.52-0.67)	<b>0.78</b> <b>(0.68-0.89)</b>
Shoulder	0.87 (0.75-1.00)	0.92 (0.79-1.06)	0.87 (0.74-1.02)	0.94 (0.79-1.10)	0.83 (0.71-0.99)	0.93 (0.79-1.11)	0.80 (0.66-0.98)	0.88 (0.72-1.08)	1.10 (0.90-1.34)	<b>1.27</b> <b>(1.04-1.56)</b>	0.98 (0.85-1.13)	<b>1.16</b> <b>(1.00-1.34)</b>
Upper arm	0.77 (0.60-1.00)	0.98 (0.76-1.27)	0.60 (0.44-0.81)	0.81 (0.60-1.11)	0.56 (0.41-0.77)	0.76 (0.54-1.05)	0.62 (0.42-0.89)	0.81 (0.55-1.19)	0.89 (0.63-1.28)	1.23 (0.85-1.80)	0.73 (0.56-0.94)	1.01 (0.77-1.33)
Elbow	0.73 (0.54-0.97)	0.77 (0.57-1.03)	0.64 (0.46-0.89)	<b>0.70</b> <b>(0.50-0.98)</b>	0.95 (0.70-1.30)	0.99 (0.72-1.37)	0.92 (0.64-1.32)	0.93 (0.64-1.37)	0.90 (0.60-1.34)	0.94 (0.62-1.42)	1.19 (0.93-1.53)	1.30 (0.99-1.70)
Forearm	0.91 (0.65-1.28)	1.08 (0.76-1.52)	0.53 (0.34-0.82)	<b>0.63</b> <b>(0.40-0.99)</b>	0.72 (0.47-1.07)	0.85 (0.55-1.30)	0.80 (0.50-1.29)	0.96 (0.59-1.55)	0.74 (0.43-1.26)	0.90 (0.52-1.54)	0.98 (0.70-1.36)	1.17 (0.82-1.65)
Wrist	0.86 (0.70-1.07)	1.07 (0.86-1.34)	0.57 (0.43-0.74)	<b>0.74</b> <b>(0.57-0.98)</b>	0.63 (0.48-0.82)	0.81 (0.62-1.07)	0.79 (0.58-1.06)	1.00 (0.74-1.37)	0.71 (0.50-0.99)	0.95 (0.67-1.34)	0.86 (0.70-1.07)	1.15 (0.91-1.44)
Hand	0.68 (0.53-0.88)	0.81 (0.62-1.05)	0.44 (0.32-0.61)	<b>0.57</b> <b>(0.40-0.79)</b>	0.47 (0.34-0.66)	<b>0.59</b> <b>(0.41-0.83)</b>	0.60 (0.41-0.87)	0.74 (0.50-1.09)	0.60 (0.40-0.91)	0.77 (0.50-1.18)	0.57 (0.44-0.75)	<b>0.74</b> <b>(0.56-0.99)</b>
Fingers	0.85 (0.66-1.10)	0.91 (0.70-1.19)	0.63 (0.46-0.86)	<b>0.72</b> <b>(0.52-0.99)</b>	0.65 (0.47-0.86)	<b>0.71</b> <b>(0.51-0.99)</b>	0.80 (0.56-1.14)	0.93 (0.65-1.34)	0.71 (0.48-1.07)	0.81 (0.53-1.22)	0.75 (0.58-0.98)	0.84 (0.64-1.11)
Thoracic spine	0.75 (0.63-0.90)	<b>0.77</b> <b>(0.64-0.93)</b>	0.83 (0.69-1.02)	0.90 (0.74-1.10)	0.71 (0.58-0.88)	<b>0.78</b> <b>(0.63-0.97)</b>	0.69 (0.54-0.89)	<b>0.74</b> <b>(0.57-0.97)</b>	0.54 (0.40-0.73)	<b>0.64</b> <b>(0.47-0.87)</b>	0.63 (0.52-0.76)	<b>0.77</b> <b>(0.63-0.93)</b>
Ribs	0.85 (0.59-1.21)	0.98 (0.68-1.42)	0.74 (0.49-1.11)	0.88 (0.58-1.34)	0.60 (0.38-0.95)	<b>0.74</b> <b>(0.46-1.17)</b>	1.04 (0.66-1.62)	1.18 (0.73-1.88)	0.69 (0.39-1.22)	0.88 (0.50-1.57)	0.78 (0.54-1.11)	0.90 (0.62-1.36)
Lower back	0.91 (0.80-1.03)	0.93 (0.82-1.06)	0.85 (0.73-0.97)	0.91 (0.78-1.05)	0.77 (0.67-0.90)	<b>0.84</b> <b>(0.72-0.97)</b>	0.69 (0.57-0.82)	<b>0.76</b> <b>(0.63-0.91)</b>	0.85 (0.71-1.03)	0.96 (0.79-1.16)	0.79 (0.70-0.90)	0.93 (0.81-1.06)
Abdomen	0.70 (0.52-0.95)	0.94 (0.69-1.28)	0.45 (0.31-0.67)	<b>0.61</b> <b>(0.41-0.91)</b>	0.68 (0.48-0.97)	0.97 (0.68-1.40)	0.67 (0.44-1.02)	0.89 (0.57-1.37)	0.91 (0.60-1.38)	1.33 (0.87-2.05)	0.60 (0.44-0.83)	0.82 (0.59-1.14)
Pelvis/Gluteals	1.00 (0.78-1.28)	1.11 (0.86-1.43)	0.77 (0.57-1.03)	0.86 (0.64-1.17)	0.92 (0.69-1.23)	1.13 (0.84-1.52)	1.02 (0.74-1.41)	1.15 (0.81-1.62)	0.96 (0.67-1.39)	1.19 (0.82-1.73)	1.10 (0.86-1.40)	<b>1.37</b> <b>(1.06-1.76)</b>
Hip	1.06 (0.87-1.30)	1.05 (0.85-1.29)	0.93 (0.74-1.17)	0.96 (0.76-1.21)	1.05 (0.84-1.32)	1.09 (0.87-1.38)	0.93 (0.71-1.22)	0.97 (0.73-1.29)	1.24 (0.94-1.63)	<b>1.37</b> <b>(1.03-1.81)</b>	0.97 (0.79-1.18)	1.17 (0.95-1.45)
Groin	0.94 (0.65-1.34)	1.04 (0.72-1.49)	0.72 (0.47-1.10)	0.80 (0.52-1.23)	0.98 (0.65-1.46)	1.05 (0.69-1.59)	1.08 (0.69-1.71)	1.20 (0.75-1.91)	1.31 (0.83-2.10)	1.40 (0.87-2.27)	1.28 (0.92-1.79)	1.40 (0.99-1.99)
Thigh	0.99 (0.75-1.31)	1.13 (0.85-1.51)	0.87 (0.63-1.19)	0.99 (0.71-1.38)	1.24 (0.92-1.68)	<b>1.41</b> <b>(1.03-1.92)</b>	1.39 (0.99-1.95)	<b>1.59</b> <b>(1.13-2.25)</b>	1.60 (1.13-2.27)	<b>1.82</b> <b>(1.28-2.61)</b>	1.37 (1.05-1.78)	<b>1.51</b> <b>(1.15-1.99)</b>
Knee	1.02 (0.88-1.19)	1.08 (0.92-1.25)	1.04 (0.88-1.22)	1.10 (0.93-1.30)	1.17 (0.99-1.37)	<b>1.25</b> <b>(1.06-1.50)</b>	1.12 (0.93-1.36)	<b>1.22</b> <b>(1.01-1.49)</b>	1.43 (1.18-1.75)	<b>1.55</b> <b>(1.27-1.90)</b>	1.16 (1.00-1.34)	<b>1.30</b> <b>(1.12-1.51)</b>
Lower leg	0.77 (0.59-1.00)	0.93 (0.71-1.21)	0.82 (0.62-1.07)	1.04 (0.78-1.39)	1.02 (0.77-1.34)	1.31 (0.98-1.73)	1.14 (0.83-1.55)	<b>1.43</b> <b>(1.04-1.97)</b>	0.95 (0.66-1.36)	1.22 (0.85-1.77)	1.03 (0.81-1.31)	<b>1.34</b> <b>(1.04-1.73)</b>
Ankle/Achilles	1.09 (0.87-1.36)	1.14 (0.90-1.43)	1.19 (0.93-1.52)	1.24 (0.96-1.59)	1.42 (1.12-1.81)	<b>1.47</b> <b>(1.14-1.88)</b>	1.48 (1.12-1.94)	<b>1.55</b> <b>(1.17-2.06)</b>	1.70 (1.28-2.26)	<b>1.79</b> <b>(1.34-2.40)</b>	1.69 (1.37-2.08)	<b>1.85</b> <b>(1.49-2.31)</b>
Foot/Toes	1.22 (0.99-1.52)	<b>1.28</b> <b>(1.02-1.60)</b>	1.12 (0.88-1.42)	1.25 (0.98-1.61)	1.08 (0.84-1.38)	1.24 (0.96-1.60)	1.10 (0.82-1.47)	1.26 (0.93-1.71)	1.23 (0.91-1.67)	<b>1.50</b> <b>(1.10-2.05)</b>	1.17 (0.94-1.45)	<b>1.53</b> <b>(1.22-1.92)</b>

Abbreviations: CI, Confidence Interval; MSK, Musculoskeletal; OR, Odds Ratio; PA, Physical Activity; WHO, World Health Organization

Footnote: A group of participants who did not meet the WHO recommendations of PA (i.e. PA less than 150 min per week) was set as the reference group. The model was adjusted for sex, age, employment status, and depression risk. The numbers in bold denote significant results, and the confidence interval that starts or ends with 1.0 derives from rounding the decimals.

**Table 3. Association of PA with the Number of MSK-Pain Locations**

<i>Number of MSK-Pain Locations</i>	<i>Dose of WHO Guideline-Based PA</i>											
	150-300 min		300-450 min		450-600 min		600-750 min		750-900 min		900+ min	
	Crude OR (95% CI)	Adjusted OR (95% CI)	Crude OR (95% CI)	Adjusted OR (95% CI)	Crude OR (95% CI)	Adjusted OR (95% CI)	Crude OR (95% CI)	Adjusted OR (95% CI)	Crude OR (95% CI)	Adjusted OR (95% CI)	Crude OR (95% CI)	Adjusted OR (95% CI)
Minimum 1 location	1.06 (0.95-1.18)	1.10 (0.98-1.23)	1.04 (0.93-1.17)	1.12 (0.99-1.27)	1.01 (0.89-1.14)	1.11 (0.98-1.26)	0.92 (0.80-1.06)	1.04 (0.90-1.20)	1.09 (0.80-1.28)	<b>1.28</b> <b>(1.10-1.51)</b>	1.05 (0.94-1.17)	<b>1.30</b> <b>(1.16-1.45)</b>
Minimum 3 locations	0.89 (0.78-1.01)	0.97 (0.85-1.11)	0.80 (0.70-0.93)	0.90 (0.78-1.04)	0.80 (0.69-0.93)	0.93 (0.80-1.08)	0.86 (0.72-1.02)	1.00 (0.84-1.19)	0.93 (0.77-1.12)	1.12 (0.93-1.36)	0.88 (0.77-0.99)	1.08 (0.94-1.23)
Minimum 5 locations	0.76 (0.62-0.93)	0.84 (0.69-1.03)	0.65 (0.51-0.82)	<b>0.75</b> <b>(0.60-0.95)</b>	0.61 (0.48-0.78)	<b>0.73</b> <b>(0.57-0.93)</b>	0.74 (0.56-0.97)	0.85 (0.64-1.13)	0.87 (0.66-1.16)	1.09 (0.82-1.45)	0.83 (0.68-1.01)	1.06 (0.87-1.29)
Minimum 10 locations	0.70 (0.45-1.07)	0.76 (0.49-1.17)	0.32 (0.17-0.61)	<b>0.36</b> <b>(0.19-0.68)</b>	0.57 (0.34-0.98)	0.64 (0.37-1.10)	0.64 (0.35-1.19)	0.67 (0.35-1.40)	0.62 (0.31-1.23)	0.70 (0.35-1.40)	0.61 (0.39-0.95)	0.67 (0.42-1.06)

Abbreviations: CI, Confidence Interval; MSK, Musculoskeletal; OR, Odds Ratio; PA, Physical Activity; WHO, World Health Organization

Footnote: A group of participants who did not meet the WHO recommendations of PA (i.e. PA less than 150 min per week) was set as the reference group. The model was adjusted for sex, age, employment status, and depression risk.



SC02

## Welcome

The outbreak of the novel coronavirus has changed our life within shortest time. In many countries, public life has been reduced or canceled (e.g. by means of business closures, bans of public gathering or quarantine) in order to reduce social contact and, with this, contain the pandemic. For many individuals, regular access to gyms, sports clubs or sports facilities is no longer possible.

We, an international group of scientists from several universities, aim to help all those being affected by the current situation. To promptly create new exercise programs, contents and methods, we conduct a brief survey assessing your physical activity levels well-being during the pandemic. Our survey will take less than 10 minutes.

SC01

The guidelines of good ethical research stipulate that participants in empirical studies explicitly and comprehensively agree to participate.

**Voluntary.** Your participation in this investigation is voluntary. You are free to cancel your participation at any time in this study without incurring any disadvantages.


**Anonymity.** Your data is treated confidentially, will be stored encrypted and password-protected, only be evaluated anonymously and not be passed on to third parties. All collected data will only be used for scientific purposes. Demographic information such as age or gender does not allow a clear conclusion to be drawn with regard to yourself.

**Questions.** If you still have questions about this study, you can find the contact details of the principal investigator of this study in the bottom of each page ('Imprint ASAP').

By participating in this survey (indicated by clicking the 'Participate'-button), I confirm that I am older than 18 years and have read and understood the informed consent.


Participate

1  
2  
3  
4  
5 **Please indicate your sex.**

SD01 

- 6  
7  Male  
8  Female  
9  
10  Non-binary  
11  I prefer not to say  
12  
13


14  
15 **What is your age?**

SD02 


16  
17  years  
18  
19

20  
21  
22 **Where do you live?**

SD04 

23  
24    
25  
26

27  
28 **Where do you work since the virus outbreak in your country?**

SD03 

- 29  
30  Remotely (Home office)  
31  Office/regular place of work  
32  both  
33  I do not have a formal employment.  
34  I do not want to tell.  
35  
36  
37  
38  
39

40  
41  
42  
43  
44  
45 **Do you currently work part-time or full-time?**

SD05 

- 46  
47  full-time  
48  part-time  
49  I do not want to tell  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59

1  
2  
3  
4  
5 **Have you had any symptoms beyond a minor respiratory tract infection since the virus outbreak in your**  
6 **country?**

KH01

7 **Only choose yes, if you had to stay in bed or reduce your regular movement behaviour due to these symptoms.**

8  
9  yes

10  no

11  
12  
13  
14  
15  
16  
17  
18  
19 **Have you been diagnosed with the novel Coronavirus?**

KH02

20  
21 Only choose "yes" if you have been diagnosed by a helathcare professional.

22  
23  yes

24  no

25  I do not want to tell

26  
27  
28  
29  
30  
31  
32  
33  
34  
35 **Please indicate the approximate number of days you have been limited in your ability to leave your home and**  
36 **move freely due to restrictions of public life (e.g. prohibition of face-to-face contact, business closures,**  
37 **lockdowns).**

KH03

38  
39  days

40  
41  
42  
43  
44  
45  
46  
47  
48  
49 From here, we will repeatedly ask how certain situations and conditions have changed in your country since the outbreak  
50 of the novel coronavirus. For instance, if you just stated to be restricted in your ability to move freely since 14 days,  
51 please always compare the situation during these last 14 days to 14 typical days prior to the outbreak. If you chose 30  
52 days, please compare these 30 days with 30 typical days prior to the outbreak.

KH04

KA09

**Physical activities in leisure time**

We would like to know, how physically active you have been in your **free time** (including commuting from and to work). We only ask about moderate and vigorous activities – light activities do not need to be reported.

Moderate activities are those where your heartbeat increases and you breathe faster (e.g. brisk walking, cycling as a means of transport or as a exercise, heavy gardening, running or recreational sports).

Vigorous activities are those that get your heart racing, make you sweat and so short of breath that you find it difficult to speak (e.g. swimming, running, cycling at high speeds, cardio training, weigh-lifting or team sports such as football).

KA01

**Moderate and vigorous activities**

On a typical week, how much time do you spend in total on both moderate and vigorous physical activities?

Please sum all activities with a minimal duration of 10 minutes. Enter 0, if there was not at least one activity of more than 10 minutes.

before the outbreak  Minutes per week.

since the outbreak  Minutes per week.

KA03

**Vigorous activities only**

How much of that time you indicated above, do you spend in total on **vigorous physical activities** only?

Please sum all activities with a minimal duration of 10 minutes. Enter 0, if there was not at least one activity of more than 10 minutes.

before the outbreak  Minutes per week.

since the outbreak  Minutes per week.



KA10

**Physical activity in your job**

While the previous questions addressed free time, the following two focus on work/occupational time. Again, we only ask about moderate and vigorous activities – light activities do not need to be reported.

Moderate activities are those where your heartbeat increases and you breathe faster (e.g. brisk walking).

Vigorous activities are those that get your heart racing, make you sweat and so short of breath that you find it difficult to speak (e.g. repeated lifting of heavy weights).

**Moderate and vigorous activities**

KA07

Rahmen

On a typical week, how much time do you spend in total on both moderate and vigorous physical activities?

Please sum all activities with a minimal duration of 10 minutes. Enter 0, if there was not at least one activity of more than 10 minutes.

before the outbreak  Minutes per week.

since the outbreak  Minutes per week.

**Vigorous activities only**

KA08

How much of that time you indicated above, do you spend in total on **vigorous physical activities** only?

Please sum all activities with a minimal duration of 10 minutes. Enter 0, if there was not at least one activity of more than 10 minutes.

before the outbreak  Minutes per week.

since the outbreak  Minutes per week.

KA11

**Please indicate the impact of the restrictions in public life on your overall level of activity (now including also light and very light activities such as shopping, walking, etc.)**

strongly negative influence



slight negative influence



no influence



modest positive impact



strongly positive influence



1  
2  
3  
4  
5 **How did you engage in sport or exercise before the virus outbreak in your country?**

KA05

6  
7 **Multiple choice possible.**

- 8  Gym  
9  
10  Sports club  
11  
12  Self-organised outdoor (e.g. running, cycling in nature)  
13  Self-organised at home (e.g. cycle ergometer, dumbbells)  
14  others   
15  
16  not at all  
17  
18  
19

20 **How did you engage in sport or exercise since the virus outbreak in your country?**

KA06

21  
22 **Multiple choice possible.**

- 23  
24  self-organised outdoor (e.g. running, cycling in nature)  
25  self-organised at home (e.g. cycle ergometer, dumbbells)  
26  
27  others   
28  
29  not at all  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

WB13

Please indicate whether you suffered from musculoskeletal pain before and/or since the virus outbreak.

The musculoskeletal system comprises all parts of the skeletal system with bones, muscles, ligaments, tendons, joints and their functions.

	no pain	very light pain	light pain	moderate pain	strong pain	very strong pain
before outbreak	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
since outbreak	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

WB14

How much did pain interfere with your normal work (including both work outside the home and housework)?

	no pain	not at all	a little bit	moderately	quite a bit	extremely
before outbreak	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
since outbreak	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

question('WB15', 'combine=WB16')

Please list all body regions where you had pain before (left boxes) and/or side (right boxes) the onsetWB15 WB16 

	before outbreak	since outbreak
<b>Multiple selections in both columns are possible.</b>		
I did not have pain.	<input type="checkbox"/>	<input type="checkbox"/>
Neck/cervical spine	<input type="checkbox"/>	<input type="checkbox"/>
Shoulder	<input type="checkbox"/>	<input type="checkbox"/>
Upper arm	<input type="checkbox"/>	<input type="checkbox"/>
Elbow	<input type="checkbox"/>	<input type="checkbox"/>
Forearm	<input type="checkbox"/>	<input type="checkbox"/>
Wrist	<input type="checkbox"/>	<input type="checkbox"/>
Hand	<input type="checkbox"/>	<input type="checkbox"/>
Fingers	<input type="checkbox"/>	<input type="checkbox"/>
Thoracic spine/upper back	<input type="checkbox"/>	<input type="checkbox"/>
Sternum/Ribs	<input type="checkbox"/>	<input type="checkbox"/>
Lumbar spine/lower back	<input type="checkbox"/>	<input type="checkbox"/>
Abdomen	<input type="checkbox"/>	<input type="checkbox"/>
Pelvis/buttock	<input type="checkbox"/>	<input type="checkbox"/>
Hip	<input type="checkbox"/>	<input type="checkbox"/>
Groin	<input type="checkbox"/>	<input type="checkbox"/>
Thigh	<input type="checkbox"/>	<input type="checkbox"/>
Knee	<input type="checkbox"/>	<input type="checkbox"/>
Lower leg	<input type="checkbox"/>	<input type="checkbox"/>
Ankle/achilles tendon	<input type="checkbox"/>	<input type="checkbox"/>
Foot/toes	<input type="checkbox"/>	<input type="checkbox"/>

Please indicate for each of the five statements which is closest to how you have been feeling before the **WB10** outbreak of the novel coronavirus.

	all the time	most of the time	a little more than half of the time	a little less than half of the time	every now and then	at no time
<b>Before the outbreak...</b>						
...I have felt cheerful and in good spirits	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
...I have felt calm and relaxed	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
...I have felt active and vigorous	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
...I woke up feeling fresh and rested	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
...my daily life has been filled with things that interest me	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

Please indicate for each of the five statements which is closest to how you have been feeling since the **WB11** outbreak of the novel coronavirus.

	all the time	most of the time	a little more than half of the time	a little less than half of the time	every now and then	at no time
<b>Since the outbreak</b>						
...I have felt cheerful in good spirits	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
...I have felt calm and relaxed	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
...I have felt active and vigorous	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
...I woke up feeling fresh and rested	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
...my daily life has been filled with things that interest me	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>



1  
2  
3  
4  
5 **How much time per week would you like to spend for such a training program?**

TP02

6  
7  Minutes per training session/workout

8  
9  
10  
11 **How often would you like to exercise?**

TP04

- 12  
13  daily  
14  4-6 times a week  
15  3-4 times a week  
16  1-2 times a week

17  
18  
19  
20  
21 **Which type of exercise would you like to perform?**

TP03

22  
23 **Multiple choice possible.**

- 24  
25  Strength  
26  Endurance  
27  Coordination/Balance  
28  Cognition  
29  Flexibility/Stretching  
30  Relaxation  
31  no preference

32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43 **Thank you for participating!**

EN04

44  
45 You are welcome to visit us on our homepage as well as on Facebook and Instagram:

EN05



51 [Homepage](#) [Facebook](#) [Instagram](#)

52  
53  
54 **Please feel free to share this survey with your family, work colleagues and friends! Thank you!**

1  
2  
3  
4 **Thank you for participating!**  
5

6  
7  
8 Your answers have been saved, you can now close the browser window.  
9

---

10  
11  
12  
13 [Imprint ASAP](#) – 2020  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



**STROBE 2007 (v4) Statement—Checklist of items that should be included in reports of *cross-sectional studies***

Section/Topic	Item #	Recommendation	Reported on page #
<b>Title and abstract</b>	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1-3
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	1-3
<b>Introduction</b>			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	3-4
Objectives	3	State specific objectives, including any prespecified hypotheses	3-4
<b>Methods</b>			
Study design	4	Present key elements of study design early in the paper	4
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	4-5
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants	5
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	5-6
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	5-6
Bias	9	Describe any efforts to address potential sources of bias	5-6
Study size	10	Explain how the study size was arrived at	5-6
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	5-6
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	5-6
		(b) Describe any methods used to examine subgroups and interactions	5-6
		(c) Explain how missing data were addressed	5-6
		(d) If applicable, describe analytical methods taking account of sampling strategy	N/A
		(e) Describe any sensitivity analyses	N/A
<b>Results</b>			

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	6
		(b) Give reasons for non-participation at each stage	N/A
		(c) Consider use of a flow diagram	N/A
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	6
		(b) Indicate number of participants with missing data for each variable of interest	N/A
Outcome data	15*	Report numbers of outcome events or summary measures	7
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	7-8
		(b) Report category boundaries when continuous variables were categorized	7-8
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	N/A
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	N/A
<b>Discussion</b>			
Key results	18	Summarise key results with reference to study objectives	8-12
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	12
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	11-12
Generalisability	21	Discuss the generalisability (external validity) of the study results	11-12
<b>Other information</b>			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	13

\*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at [www.strobe-statement.org](http://www.strobe-statement.org).